University of Tennessee Health Science Center

UTHSC Digital Commons
Theses and Dissertations (ETD)

College of Graduate Health Sciences

8-2022

Ribonucleotide Reductase Subunit Switching in Hepatoblastoma
Drug Response and Relapse
Anthony Brown
University of Tennessee Health Science Center

Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Neoplasms Commons, Oncology Commons, Pediatrics Commons, and the Therapeutics
Commons

Recommended Citation
Brown, Anthony (https://orcid.org/0000-0003-4408-3998), "Ribonucleotide Reductase Subunit Switching
in Hepatoblastoma Drug Response and Relapse" (2022). Theses and Dissertations (ETD). Paper 611.
http://dx.doi.org/10.21007/etd.cghs.2022.0601.

This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC
Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized
administrator of UTHSC Digital Commons. For more information, please contact jwelch30@uthsc.edu.
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and Relapse
Abstract
Hepatoblastoma is the most common primary liver cancer in infants and young children. Despite being a
very rare cancer that accounts for only 0.5-2% if all childhood cancer cases, HB has the largest increase in
incidence among childhood cancers in the United States and worldwide. The five-year survival rate of
children with the aggressive forms of HB, including those that have developed metastatic or recurrent
diseases, is less than 40% due to the lack of effective treatment. We aim to identify targetable
mechanisms underlying the progression and drug resistance of high-risk HB. Our recent work on HB
mouse and organoid models, patient-derived xenografts (PDX) and primary patient samples revealed a
significant upregulation of ribonucleotide reductase (RNR) subunit M2 (RRM2) in high-risk HB. RNR is the
sole enzymatic complex in mammal cells that converts ribonucleotides to deoxyribonucleotides and
plays a critical role in regulating cell division and DNA repair. We found standard chemotherapy agents as
well as two RRM2 inhibitors, triapine and MK1775, werecapable of reducing RRM2 expression effectively
in vitro. However, we found a significant induction of another RNR subunit M2B (RRM2B) in treated cells
in corresponding to RRM2 reduction. While no changes in drug response were noticed in RRM2B
knockout (KO) HB cells. RRM2B levels in HB cells showed a strong impact on cells’ ability to recover after
chemotherapy. RRM2BOE HB cells showed a significant increase in their colony formation potential after
chemotherapy where RRM2BKO cells formed much fewer colonies after treatment compared to the
control cells. Interestingly, we noticed a reversed subunit switch from RRM2B to RRM2 during the
recovery period when cell proliferation was restored. RRM2, indeed, had a much higher enzymatic activity
in converting ribonucleotides to deoxyribonucleotides than RRM2B and promoted cell growth much more
efficiently than RRM2B when both were overexpressed in HB cells. Finally, combining the RRM2 inhibitor
MK1775 with standard chemotherapy in HB PDX models, although showing no additional benefit in
reducing tumor size, significantly delayed tumor relapse after drug withdrawal. In this study, we
demonstrated an intriguing switching between two RNR subunits, RRM2 and RRM2B in HB cells
undergoing drug treatment and during their recovery afterwards. Our data suggest that RRM2 supports
HB growth while its switching to RRM2B is critical to tumor cell survival under drug treatment. When
tumor relapses, there is a reversed subunit switch from RRM2B to RRM2 to supports the recurrent growth
of the tumor, which can serve as a potential therapeutic target in preventing HB relapse.
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ABSTRACT
Hepatoblastoma (HB) is the most common primary liver cancer in infants and
young children. Despite being a very rare cancer that accounts for only 0.5-2% of all
childhood cancer cases, HB has the largest increase in incidence among childhood
cancers in the United States and worldwide. The five-year survival rate of children with
the aggressive forms of HB, including those that have developed metastatic or recurrent
diseases, is less than 40% due to the lack of effective treatment. We aim to identify
targetable mechanisms underlying the progression and drug resistance of high-risk HB.
Our recent work on HB mouse and organoid models, patient-derived xenografts
(PDX) and primary patient samples revealed a significant upregulation of ribonucleotide
reductase (RNR) subunit M2 (RRM2) in high-risk HB. Ribonucleotide reductase (RNR)
is the sole enzymatic complex in mammal cells that converts ribonucleotides to
deoxyribonucleotides and plays a critical role in regulating cell division and DNA repair.
We found standard chemotherapy agents as well as two RRM2 inhibitors, triapine and
MK1775, were capable of reducing RRM2 expression effectively in vitro. However, we
found a significant induction of another RNR subunit M2B (RRM2B) in treated cells in
corresponding to RRM2 reduction. While no changes in drug response were noticed in
RRM2B knockout (KO) HB cells. RRM2B levels in HB cells showed a strong impact on
cells’ ability to recover after chemotherapy. Overexpression (OE) of RRM2B in HB cells
showed a significant increase in their colony formation potential after chemotherapy
where RRM2BKO cells formed much fewer colonies after treatment compared to the
control cells. Interestingly, we noticed a reversed subunit switch from RRM2B to RRM2
during the recovery period when cell proliferation was restored. RRM2, indeed, had a
much higher enzymatic activity in converting ribonucleotides to deoxyribonucleotides
than RRM2B and promoted cell growth much more efficiently than RRM2B when both
were overexpressed in HB cells. Finally, combining the RRM2 inhibitor MK1775 with
standard chemotherapy in HB PDX models, although showing no additional benefit in
reducing tumor size, significantly delayed tumor relapse after drug withdrawal.
In this study, we demonstrated an intriguing switching between two RNR
subunits, RRM2 and RRM2B in HB cells undergoing drug treatment and during their
recovery afterwards. Our data suggest that RRM2 supports HB growth while its
switching to RRM2B is critical to tumor cell survival under drug treatment. When tumor
relapses, there is a reversed subunit switch from RRM2B to RRM2 to supports the
recurrent growth of the tumor, which can serve as a potential therapeutic target in
preventing HB relapse.
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CHAPTER 1.

INTRODUCTION

Hepatoblastoma
Hepatoblastoma (HB) is extremely rare accounting for only 1% of all
malignancies in the pediatric age group, with less than 1.5 cases per million children
under the age of 18.1 HB, which makes up more than two-thirds of the pediatric liver
malignancies has recently been reported to have the highest increase in incidence rates
of pediatric malignancies possibly due to the increased number of survivors of
premature birth and the predisposition to develop HB in infants with a birth weight
lower than 1500g.2 With the advancement of surgical procedures and chemotherapy,
the 5-year overall survival rate has reached greater than 80%.3
However, about one fifth of patients with HB have lung metastasis at the time of
diagnosis.4, 5 For children with metastatic HB, the survival rate drops dramatically, a
recent study looking exclusively at children with metastatic HB showed a 5-year overall
survival rate of just 23.7%.6

Challenges in Hepatoblastoma Research
Clinical and basic research on HB remains challenging due to a small patient
population and limited research resources. Over a 15-year period from 1994 to 2006 the
Society of Pediatric Oncology Liver Tumors Strategy Group (SIOPEL) performed 2
international clinical trials to test therapeutic strategies on high-risk HB with a total
patient number of 216.7 In comparison to a more common pediatric solid, neuroblastoma,
which is the most common extra-cranial solid tumor in infants and children,8 between the
years 1991-2020 there were 9087 children enrolled in 2 international clinical trials.9
The rarity of HB has also limited the number of research models available for HB.
There are currently on two cell lines publicly available for HB; HepG2 and Huh6, with
both being from low grade tumors.10Similar to cell lines, there is a lack of mouse models
available as well. As of six years ago there were only around 4 reported transgenic mouse
models that were able to produce HB tumors and one of them only produced tumors 38%
of the time.10 Patient-derived xenografts (PDXs) have been established for HB in recent
years, however, metastasis are rare in either HB genetic or PDX mouse models.
Highlighting the need for new research models for HB and more specifically models that
recapitulate the more advanced disease state.

Development of a Metastatic HB Mouse Model in Our Laboratory
Our lab has reported the development of a HB genetic mouse model,
Prominin1CreERT2;NICD1 (Notch intercellular domain 1)/+; RosaZsG (PNR) mouse
(Figure 1-1) in which the Notch signaling pathway was activated in Prom1-expressing
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Figure 1-1.

Schematic diagram of PNR mouse model.

2

liver progenitor population in neonatal mice to drive HB development.11 Notch has been
shown to play an important role in the development, repair, and homeostasis of the
liver.12 Detailed histopathological review has confirmed that tumors generated in our
PNR model recapitulate the fetal and embryonal subtypes of HB.11 These tumors
expressed common HB diagnostic markers such as β-catenin (Ctnnb1) and glutamine
synthetase (GS).11 While this PNR model was able to produce HB in neonatal mice, it
had a low metastasis rate of 1.9%.13
In order to develop a high-risk HB mouse model that would allow us to gain
further insight into the biological mechanisms driving advanced progression of HB, our
lab chose a cancer stem cell (CSC) based approach to promote metastasis in the PNR
model. CSCs have been widely reported to be tightly associated with advanced cancer
development such as metastasis, drug resistance, and relapse.14 Recent 3D organoid
models provided an efficient means to enrich CSCs from primary tumors.15 To enrich the
potential metastatic initiating CSCs from the PNR tumors, our lab isolated primary
tumors from the PNR mouse model and cultured the tumor cells in a 3D cell culture
system using Matrigel as the base and a chemically defined medium for liver cancer
cells.13 These organoids could be readily established from the primary PNR tumors and
showed a consistent and significant upregulation in the expression of liver stem cell
markers compared to their parental tumors. They were then orthotopically transplanted
into CD-1 nude mice where a subset of the organoids were highly tumorigenic and
metastatic (Figure 1-2). The metastatic rates for these tumorigenic organoids
significantly increased to 28-42%, a drastic increase from the parental PNR model.13 By
using a cancer organoid based approach, our lab was able to generate a highly efficient
model of high-risk HB.

Upregulation of Ribonucleotide Reductase M2 in HB Metastasis
In order to determine potential drivers behind the increased metastasis observed in
the organoid transplantation model, we performed a large RNAseq transcriptomic
comparison of the primary tumors in the genetic models and metastatic tumors in the
organoid transplantation model, as well as the PNR organoids with the normal organoids
grown from wildtype mouse liver. We found Ribonucleotide reductase M2 (RRM2) to be
one of the top genes significantly upregulated in the highly tumorigenic PNR organoids
and metastatic tumors. RRM2 is essential for proliferating cells and catalyzes the
formation of deoxyribonucleotides for DNA synthesis.16 It has been reported to be
upregulated in several other cancers including breast, cervical, lung, and adult liver
cancer.17-20 We confirmed that RRM2 expression was tightly associated with HB
progression in patients, with higher grade tumors showing high levels or RRM2
expression. There have been several inhibitors that have been developed to target RRM2
or the RNR complex, two of which are triapine and MK1775.21, 22 When testing these
RRM2 inhibitors as well as standard chemotherapies were used on the HB cell line
HepG2, we found that all treatments were able to effectively lower RRM2 protein levels
which was expected due to the various mechanisms in which they inhibit proliferation.
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Figure 1-2.

Schematic diagram of orthotopic transplantation model.
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Interestingly, we found that and isoform of RRM2, ribonucleotide reductase subunit M2B
(RRM2B), was significantly induced by treatment. This dynamic switching from RRM2
to RRM2B following drug treatment was also found in a HB PDX cell line that was
developed in a collaborating lab, as well as HB214 PDX tumors in vivo. We found that
RRM2B has a much lower expression in treatment naïve cells and tumors and was not
associated with HB progression in patients. Although RRM2B has been associated with
stress response23 its role in cancer is unclear. Our finding on this drug-induced RRM2 to
RRM2B switching in HB cells and tumors suggests that these two RNRM2 isoforms
might have distinct role in HB development and drug response.

Hypothesis and Specific Aims
Drug treatment-induced switching of the two RNR2 subunits, RRM2 and
RRM2B, is critical to HB cell survival and drug resistance.
I propose to test this hypothesis via the following two specific aims to determine
the biological functions of RRM2 and RRM2B in HB development and drug resistance,
and the effects of their pharmacological inhibition on advanced HB development.
Successful completion of this project will yield essential evidence to support RNR as a
novel therapeutic target of high-risk HB.

Aim 1: Elucidate the Function of RRM2 and RRM2B in HB Development and Drug
Resistance
To determine the role of RRM2 and RRM2B in HB development and drug
resistance, we will use genetic approaches to up- and down-regulate RRM2 and RRM2B
expression in HB cells and test their effects on HB cell growth, drug resistance, and longterm cell survival.

Aim 2: Determine if RNR Is a Potential Therapeutic Target for HB
The high expression of RRM2 in aggressive HB tumors suggests that targeting
RRM2 enzymatic activity may serve as an effective therapeutic strategy for high-risk HB
patients. RRM2 inhibitors have been previously developed and showed a promising
efficacy in treating many refractory adult cancers such as colorectal, breast and ovarian
cancers, particularly when combined with standard chemotherapies. Upregulation of
RRM2B in response to drug treatments could lead to a novel targeting strategy in
combination with our chemotherapy agents. We will determine the efficacy of RRM2
inhibitors either targeting RRM2 directly or upstream targets as monotherapies and in
combination with standard chemotherapies. We will identify the most effective in vitro
treatment and validate their efficacy using PDX’s in vivo.

5

The proposed study will determine the therapeutic value of RRM2 and RRM2B
and potentially lead to a novel target for drug design as well as mechanistic insights into
the role of RNR in HB drug resistance.
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CHAPTER 2.

PEDIATRIC LIVER CANER, RNR, AND DRUG RESISTANCE

Pediatric Liver Cancer

Hepatoblastoma
HB occurs typically within the first 3 years of life and is possibly congenital in
familial syndromes, such as Beckwith Weidmann syndrome, Simpson-Golabi-Behmel
syndrome, Sotos syndrome, familial adenomatous polyposis coli, and constitutional
trisomy 18.24, 25 HB is exceedingly rare in children above age of five where HCC is the
most diagnosed liver cancer.26,27 In pediatric liver cancer, alpha fetoprotein (AFP) is the
most important biomarker, which is elevated in 90% HB caces.28 AFP levels are usually
extremely high in neonates (500,00 ng/mL) but decrease throughout infancy. This can
sometimes make it difficult for clinicians to determine if an individual’s AFP level is
within a normal range.29 Similarly, some benign tumors such as infantile hemangiomas
and mesenchymal hamartomas show an increased level of AFP expression and so AFP
maker by itself, cannot confirm HB.29

HB Cell of Origin
HB is an embryonal tumor that is derived from hepatic precursor cells (HPC) at
various maturation stages and that frequently contains heterogenous cell types. HB can
show various levels of epithelial or mesenchymal differentiations.30 The epithelial
components of hepatoblastomas exhibit features of embryonal and fetal development.30
Immunohistochemistry (IHC) and electron microscopy in HB shows small epithelial cells
with a phenotypic characteristic somewhere between hepatic and biliary cells. These cells
have expression of CK-7, albumin, and OV-6 which are expressed in oval stem cells
typical in adult liver.31

HB Molecular Subtypes
The term “hepatoblastoma” was introduced in 1962 based on the presence of
hepatic epithelial parenchyma resembling fetal or embryonal liver. The current
classification has been broken down into an epithelial subtype which is further broken
down into fetal and embryonal, and a mixed epithelial and mesenchymal type. The
classification of HB must be performed on pre-treated samples as post-treatment
specimens may show areas of HB indistinguishable from HCC or well-differentiated fetal
(WDF) HB morphology as a consequence of therapy-induced differentiation/maturation.32 The Pretreatment extent of tumor (PRETEXT) system is used to help
determine the classification of HB and HCC tumors, which consists of two components,
the PRETEXT group and annotation factors. The PRETEXT group describes the extent
of tumor within the liver while the annotation factors help to describe the associated
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features such as vascular involvement (portal vein or hepatic/inferior vena cava),
extrahepatic disease, multifocality, tumor rupture, and metastatic disease (to both lungs
and lymph nodes).33

Epithelial Hepatoblastoma
Epithelial HB is broken down into many different subtypes such as WDF and
small cell undifferentiated (SCU). WDF HB is composed of small uniform cells with a
central nucleus without nucleoli and an abundant eosinophilic or clear cytoplasm (Figure
2-1A).34 The cells arrange in trabeculae one to two cells thick and rarely may be in an
acinar arrangement. The diagnosis of WDF can only be made on pretreated primary
resected tumors. Immunostaining of WDF HB shows strong positive expression of
glutamine synthetase while β-catenin usually appears membranous and cytoplasmic. The
diagnosis of pure WDF HB identifies as a very low-risk patient group.27, 35
Another subtype of epithelial HB is SCU which, in the past was assigned the
worse prognosis, and was represented as the “anaplastic variant of HB”.36 HB with a
SCU phenotype have a high nuclear to cytoplasmic ratio, pale vesicular to
hyperchromatic nucleus, scant cytoplasm, and indistinct cell borders (Figure 2-2A, B).27,
36
SCU areas are difficult to distinguish post chemotherapy and like WDF should be
diagnosed prior to treatment.27, 36

Mixed Hepatoblastoma
Mixed HB is comprised of both epithelial and mesenchymal elements. The most
common mesenchymal elements are osteoid and cartilage with muscle, fat, primitive
spindle cell mesenchyme being less frequent (Figure 2-3A, B).27, 37 These components
are features of this tumor subtype and not a result of chemotherapy or other changes.

Genetics of HB
HB tumors are for the most part, genetically simple. In a study of 112 patients
with pediatric liver tumors, somatic mutations in the exonic regions were very rare (.52
per Mb on average).38 There were 26 genes that were the most frequently mutated in a
cohort including CTNNB1, ARID1A, TERT (promoter region), ITPR2, APC, and glycogen
synthase kinase-3β (GSK)-3β.38 The most common underlying mutation in HB patients is
a mutation in CTNNB1, with the incidence of such mutation in several independent
studies ranging from 46% to 89% and an average of approximately 60%.39 Mouse models
for HB induced by anthraquinone, oxazepam, or diethanolamine strikingly all showed a
100% incidence of β-catenin mutations.40, 41 These mutations in the Wnt signaling
pathway in HB which are predominantly a deletion in exon 340 lead to over activation of
this pathway.42, 43 Another study of 125 HB cases divided the patients into three groups
based upon age: “tween HB (age> 8, 6 cases)”, ”child HB (age = 2-8, 38 cases)”, and
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Figure 2-1. Well differentiated hepatoblastoma histology.
Staining of WDHB showing cells with round, centrally placed nuclei. (H&E, 400x).
Reprinted by permission from Nature Springer: Modern Pathology. Towards an
international pediatric liver tumor consensus classification: proceedings of the Los
Angeles COG liver tumors symposium., López-Terrada, D., Alaggio, R., de Dávila, M. et
al. 2014. https://doi.org/10.1038/modpathol.2013.80 [34].
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Figure 2-2. Small cell, undifferentiated hepatoblastoma histology.
(A) Small cells forming a sheet on the left are in contrast to the appearance of fetal
histology in the center and embryonal histology on the right (H&E, 200x). (B) Small cells
intermingling with hepatoblastoma cords exhibiting embryonal histology (H&E, 400x).
Reprinted with permission. Haas JE, Feusner JH, Finegold MJ. Small cell
undifferentiated histology in hepatoblastoma may be unfavorable. Cancer 2001;92:31304http://dx.doi.org/10.1002/1097-0142(20011215)92:12<3130::aid-cncr10115>3.0.co;2-#.
[36].
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Figure 2-3. Mixed hepatoblastoma histology.
(A.) Mixed hepatoblastoma: Fetal subtype admixed with islands of osteoid (H&E, 100x).
(B.) Mixed hepatoblastoma: Epithelial component admixed with cartilage, osteoid, and
smooth muscle with immature mesenchyme in the background (H&E, 400x). Reprinted
with permission. Kiruthiga KG, Ramakrishna B, Saha S, et al. Histological and
immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and
survival. J Gastrointest Oncol 2018;9:326-337.
http://dx.doi.org/10.21037/jgo.2018.01.08. [37].
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“infant HB (age <2, 81 cases)”.44, 45 TERT promotor mutations were highly enriched in
tween HB cases.44 Deletion of the exon 3 region in β-catenin was observed at a higher
rate in child HB.45 One study, looking specifically at germline mutations in HB, found
that they occur at a relatively low rate (3.1%) of the 147 patients sampled.46 APC
germline mutations were the most common in 5 of the 9 patients and interestingly,
germline mutations of APC were mutually exclusive with somatic β-catenin mutations.46

WNT/β-Catenin Pathway
The WNT/β-catenin pathway is complex due to the high number of ligands and
receptors involved as well as the variety of intracellular responses it can elicit (Figure
2-4).47 This signaling pathway is highly conserved and plays an important role in key
functions including cell proliferation, differentiation, migration, genetic stability,
apoptosis, and stem cell renewal.48 In the canonical pathway, β-catenin is the major
intracellular transducer and plays an important role in the entire pathway. The activation
of β-catenin is controlled by a complex consisting of APC, AXIN-1, AXIN-2, casein
kinase -1α, protein phosphatase 2A, and GSK-3β.49 As previously mentioned, several of
these genes, β-catenin, APC, and GSK-3β all have frequent germline and somatic
mutations in HB patients, highlighting the importance of this pathway in HB
development.

Notch Signaling Pathway
The Notch signaling pathway plays an important role in normal liver development
through its role in maintenance, morphogenesis, and proper development of the biliary
tree.12 There are four different Notch receptors, NOTCH1, NOTCH2, NOTCH3, and
NOTCH4 as well as five canonical ligands, Delta-like 1 (DLL1), DLL3, DLL4, Jagged 1
(JAG1), and JAG2. Among these receptor-ligand pairs, NOTCH2-JAG1 seems to be the
most important for liver development and has been associated with developmental
disorders such as Alagille syndrome.12 For normal liver development hepatoblasts
differentiate into hepatocytes or cholangieocytes. NOTCH2 however, has been shown to
delay this maturation process and is overexpressed in 92% of HB.50 Another member of
the Notch signaling pathway, DLK1, which is a marker for bi-potential liver precursor
cells (hepatoblasts), has also shown to be elevated in HB51 suggesting that NOTCH2 is
maintaining the hepatoblast population during development resulting in HB.

Treatment and Drug Resistance of Hepatoblastoma
The most common therapy for patients diagnosed with HB is complete surgical
resection, but the surgical procedure varies from organization to organization.52 Tumors
that have been defined as very low risk using the PRETEXT system can be recommended
for resection without prior chemotherapy.28 If patients are deemed low-risk, then it is
suggested to perform upfront resection followed by adjuvant treatment. For the
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Figure 2-4. Wnt/β-catenin pathway.
Wnt proteins bind to frizzled receptors and the LRP co-receptor which acts to suppress
the activity of glycogen synthase kinase-3β (GSK-3β). This prevents phosphorylation of
downstream molecules allowing β-catenin association with TCF/LEF transcription
factors in the nucleus and upregulation of their target genes. Adapted with permission
from “Wnt Beta-Catenin Signaling Pathway”, by BioRender.com (2022). Retrieved from
https://app.biorender.com/biorender-templates.
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intermediate to high-risk groups, they receive neoadjuvant chemotherapy prior to
resection, then adjuvant treatment as well.28 The chemotherapy regiment for HB is either
C5V, which is a combination of cisplatin, 5- fluorouracil, and vincristine for low-risk
patients, or C5VD, which is similar to C5V with the addition of doxorubicin for higher
risk patients.28 Tumor size and vascular invasion were significant predictors of metastatic
disease in univariate analysis; moreover, tumor size at diagnosis and vascular invasion
were also significant independent factors.32 Resection of the tumor should be done prior
to long term exposure to chemotherapy due to the risk of drug resistance which has been
reported.28 Patients with tumors that show resistance to chemotherapy or are diagnosed at
a very-high risk stage are referred for liver transplantation. While rare, metastasis and
relapse do occur in patients at a rate of 20% and 12% respectively.53, 54 Patients where
tumor resection or liver transplantation is possible have a 5 year overall survival rate of
~90%.55 however, for patients that are unable to have surgery or relapse following
treatment the survival rate drops drastically to 35% and 43% respectively.53, 55

Hepatocellular Carcinoma
HCC represents the other ~20% of malignant pediatric liver tumors. HCC is
usually more clinically challenging compared to HB as tumors present themselves as
large, unresectable lesions.27 HCC is commonly found more in the later years of
adolescence and is more frequent in males than females (3:1).56 HCC in children is
usually split into two groups; The first are those associated with metabolic or genetic
diseases such as hemochromatosis, hereditary tyrosinemia, progressive familial
cholestasis, bile salt export pump disease, multidrug resistance protein 3 defect and tight
junction protein 2 deficiency, alpha-1-antitrypsin deficiency, glycogen storage diseases,
and less often, biliary atresia and viral hepatitis.27 The second group arises in patients
without chronic liver illness. Fibrolamellar HCC (FL-HCC) is a subtype found more
commonly in children and has a greater survival when compared to non-fibrolamellar
subtypes (57% vs 28%).57 Differences in the epidemiology of HCC largely is a result of
the prevalence of perinatally acquired HBV infection. In certain areas of the world HCC
has been reported as the most common pediatric liver malignancy.58 In contrast to HB,
recent data has shown that the incidence rate of pediatric HCC is declining in some
areas59 or has remained relatively stable over the last 20 years57 possibly due to the
introduction of the hepatitis B vaccine.

HCC Cell of Origin
Due to pediatric HCC accounting for only .4% of all childhood malignances60,
and limited data having been published, the origin of HCC was debated for quite a while.
Recent studies have shown that HCC originates from mature hepatocytes not HPC’s.61, 62
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HCC Molecular Subtypes
Pediatric HCC uses the same system as HB for its staging and classification,
PRETEXT. These tumors, histologically, are broken down into three main classifications,
well differentiated (WD), moderately differentiated (MD), and poorly differentiated (PD)
tumors as well as FL-HCC which has some distinct characteristics that don’t fit into the
other subtypes.

Well Differentiated HCC
WDHCC presents itself as a uniform tumor of hepatocytes arranged in trabeculae
at least 3 cells think with frequent bile production. The nodule is usually separated from
the surrounding liver by a distinct pseudocapsule. The individual cells have a vacuolated
cytoplasm with round nuclei and mild nuclear pleomorphism. Staining of WDHCC
shows variable expression of GPC3 and GS with negative β-catenin nuclear staining.63, 64

Moderately Differentiated HCC
MDHCC has a larger cell arrangement with trabeculae 15 to 20 cells thick, lined
with sinusoids and moderate bile production. The cells themselves have large nuclei with
prominent nucleoli as well as an abundance of cytoplasm with eosinophilic cytoplasmic
globules. About 50% of MDHCC show positive GPC3 and HS staining. Similar to
WDHCC, β-catenin is low to negative with a few tumors showing weak nuclear
expression.27

Poorly Differentiated HCC
PDHCC contains sheets or nests of small cells that no longer resemble
hepatocytes. The nuclear to cytoplasmic ratio is high with a large degree of nuclear
pleomorphism. Numerous spots of necrosis and mitosis are noted throughout the tumor.
Unlike WD and MD HCC, nuclear expression of β-catenin is strong and diffuse as well
as strong GPC3 staining65

Fibrolamellar HCC
FL-HCC is a distinct subtype of HCC that has a propensity to arise in younger
patients and account for 24 of pediatric HCC cases.57 FL-HCC is characterized by large
abnormally shaped cells with a low nuclear to cytoplasmic ratio and abundant
eosinophilic cytoplasm.60 These tumors show fibrous and lamellar stroma through out
and have a central stellate scar.66 FL-HCC is also characterized by the presence of a
DNAJB1-PRKACA chimeric transcript that has been reported in 100% of cases due to
400-kilobase deletion on chromosome 19.67
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Genetics of Pediatric HCC
Pediatric HCC has been reported to have numerous genetic alterations including
gain of chromosomes 1q, 8q, 17q and loss of chromosomes such as 4q. Gene expression
profile of HCC patients have found abnormalities in important signaling pathways
including TP53, mitogen activated protein kinase, WNT/β-catenin, epidermal growth
factor, and transforming growth factor-beta pathways specifically in hepatitis-associated
HCC.27, 42, 68

Treatment of Hepatocellular Carcinoma
Unfortunately, pediatric HCC usually presents itself as largely chemoresistant. Up
till now, surgical resectability is the biggest prognostic predictor upon diagnosis.69 Other
determinants include lymphovascular invasion, extrahepatic disease, and metastatic
disease. Children diagnosed with HCC usually present at the more advanced stage with
only 20% of the tumors able to be resected upon diagnosis.70 There have been treatment
regimens designed for pediatric HCC with the main one being a combination of cisplatin
and doxorubicin (PLADO). A SIOPEL-1 study analyzed the outcome of 37 pediatric
HCC patients, who received PLADO treatment prior to surgical resection. A partial
response was measured in 49%, while no response or disease progression was observed
in the rest. Resection was possible for 17 (46%) of the 37 children with resection being
successful in 36%. At a follow up of 75 months, the survival rate of the children was only
28%.60 For tumors that are not resectable following treatment, the only curative option is
liver transplantation similar to HB. There have been some more recent studies on the
effect of sorafenib, a multi-kinase inhibitor against Raf and vascular endothelial growth
factor receptor, which showed promising therapeutic effects in adults and is currently
being examined in children.71 Due to the limited effective treatments for pediatric HCC,
only 20% to 30% of HCC patients respond to therapy, highlighting the need for more
effective treatments of pediatric liver malignancies.72

Ribonucleotide Reductase
Ribonucleotide reductase (RNR) is a heterodimeric tetramer that is responsible for
the generation of deoxyribonucleotides from ribonucleotides for DNA synthesis and
repair.73 RNR consists of two ribonucleotide reductase M1 (RRM1) subunits and two
Ribonucleotide reductase M2 (RRM2) or M2B (RRM2B) subunits.74 In cellular
organisms, RNRs synthesize the four deoxyribonucleoside triphosphates (dNTPs)
required for DNA replication and repair by removal of the 2’-OH of a ribonucleoside dior triphosphate molecule via a stable tyrosyl radical.73 This catalytic activity requires
oxygen to produce the tyrosyl radical by a non-heme Fe-O-Fe center in the smaller
RRM2 subunit.74 As the driver for maintaining the homeostatic levels of all four of the
dNTPs, RNR is also highly important in cancer development. Uncontrolled proliferation,
which is a defining feature of cancer, must be supported by a balanced supply of dNTP.16
If dNTPs levels are insufficient or even elevated, this will cause replication stress and
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further promote genomic instability and increased mutagenesis.75, 76 Enhanced
mutagenesis via imbalanced dNTP levels occurs mainly by two mechanisms, DNA
misinsertion and impaired proofreading.76, 77 Excess levels of dNTPs can lead to
competition between different nucleotides for pairing to the template base which will
result in misincorporation. DNA polymerase proofreading is also reduced in the presence
of excess dNTP levels through a phenomenon known as next-nucleotide effect. This
results from the chain extension occurring before the mismatched nucleotide can be
removed.78

Ribonucleotide Reductase Subunits

RRM1 Regulation and Expression
RRM1 is the large subunit of the ribonucleotide reductase (RNR) complex and
has been shown to act as the scaffold. It contains part of the substrate binding site as well
as binding sites for allosteric regulators.79 In non-proliferating or quiescent cells RRM1
levels cannot be detected whereas in proliferating cells RRM1 protein shows a consistent
level throughout the cell cycle.80, 81 Interestingly, RRM1 mRNA levels vary during the
cell cycle with minimal levels being expressed during G0/G1 and maximal levels being
reached during S phase.82

RRM1 in Cancer
Even though RRM1 acts as the scaffold for the RNR complex, many studies have
been done both preclinically and clinically that suggest it plays a more important role in
cancer. Studies have shown that RRM1 is involved in the suppression of cell migration
and metastases.79 Some preclinical data has shown its overexpression in Ras-transformed
fibroblasts limited tumor development and metastasis suggesting that RRM1 is a tumor
suppressor.83 In addition, overexpressing RRM1 using an adenovirus in lung carcinomas
had a protective effect and increased the transgenic mice survival.84 Conversely, other
studies have shown that inhibiting RRM1 through shRNA significantly inhibits the cell’s
ability to replicate.85
RRM1 has been shown to be associated with gemcitabine resistance when lung
cancer cell lines are incubated with the drug. Investigators noticed an increase in RRM1
mRNA and protein in a dose dependent manner with gemcitabine incubation in the
culture media.86 Gemcitabine resistance in RRM1 overexpressing cells has also been
evaluated in NCI-H23 non-small cell lung cancer (NSCLC) cells which showed a threefold increase in RRM1 expression and a twelve-fold increase in the 50% inhibitory
concentration (IC50) when compared to the control cells.87 The role of RRM1 in
gemcitabine resistance has also been verified with the reversion of RRM1 expression.
Using siRNA to inhibit RRM1 in gemcitabine resistant MIA PACa-2 pancreatic cancer
cells showed an increase in gemcitabine sensitivity similar to the parental cells.88
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Increased sensitivity to gemcitabine has also been reported in other cancers infected with
RRM1 siRNA including lung, biliary tract, and pancreatic.87, 89-91 Clinically RRM1 has
been associated with gemcitabine resistance as well. One study in NSCLC performed a
randomized trial including 100 patients with advanced stage disease, comparing
gemcitabine and cisplatin versus gemcitabine, cisplatin, and vinorelbine versus
gemcitabine and vinorelbine followed by vinorelbine and ifosamide. In the group with 20
patients treated with gemcitabine and cisplatin there was a significant increase in overall
survival (13.7 months vs 3.6 months) and progression-free survival (8.4 months vs 2.7
months) in patients with low RRM1 mRNA expression compared to those with high
RRM1 expression.92 Another study showed that patients with high RRM1 expression had
significantly poorer clinical outcomes and was also associated with poorer overall
survival on adjuvant chemotherapy in pancreatic cancer.93 All this together shows that
RRM1 is important in cancer progression and resistance to chemotherapy treatment.

RRM2 Regulation and Expression
RRM2 acts as the rate limiting step for the catalytic formation of
deoxyribonucleotides as its expression level is tightly regulated by cell cycle.73 RRM2 is
both regulated at the transcriptional level as well as at the protein level by enzymatic
degradation. Several transcription factor binding sites have been identified in the RRM2
promotor including one for E2F4, which represses RRM2 expression during G1 and one
for E2F that regulates enzymes involved in DNA replication.94, 95 At amino acids 30-32,
RRM2 contains a KEN box, which binds to Cdh1-anaphase-promoting complex that
forms during mitosis which leads to ubiquitination and subsequent degradation via the
proteosome.76, 96, 97 RRM2 amplification has been reported in studies that looked at
hydroxyurea resistance in human cells lines.98 Human RRM2 gene amplification from a
homogenous staining chromosome region always accompanied altered transcriptional
regulation. Cell line clones that were resistant to either gemcitabine or hydroxyurea
showed a unique binding pattern of several transcription factors including activator
protein 1 (AP-1), Sp1, cyclic AMP (cAMP)-response element binding protein (CREB),
and nuclear factor kappa-β (NF-κβ).99 DNA damage which activates checkpoint kinase 1
(Chk1) can upregulate RRM2 expression through the E2F1 transcription factor.100
Upregulation of nuclear factor Y (NF-Y) which is induced by the inhibition of histone
deacetylases (HDAC) or activation of the HIF-1α/STAT3 signaling pathway have both
been shown to increase RRM2 transcription and contributes to gemcitabine resistance.101,
102
More recently there have been several studies that have shown the importance of long
non-coding RNA (lncRNA)/microRNA (miRNA) in the role of RRM2 regulation.103-105

RRM2 in Cancer
Both RRM1 and RRM2 work together to perform the enzymatic function of RNR
and other physiological functions, and as previously mentioned, RRM1 upregulation has
been shown to confer resistance to gemcitabine. Although gemcitabine specifically
targets RRM1, both overexpression of RRM1 and RRM2 was found to establish
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gemcitabine resistance in pancreatic cell lines.106 This suggests that these two subunits
play a role together in catalysis and regulation of drug resistance. However, RRM2 is
increased during late G1 and early S phase of the cell cycle while RRM1 levels remain
relatively constant.80 Due to its more complex and varible regulation mechanisms
compared to RRM1, RRM2 maybe even more important in the occurrence of
chemoresistance. Studies have found that in chemoresistance samples, both mRNA and
protein levels of RRM2 were elevated. Microarray data of Doxorubicin (DOX) resistant
breast cancer lines showed high expression of RRM2.107 Peripheral blood samples from
imatinib-resistant patients showed increased RRM2 mRNA levels.108 Another patient
microarray dataset showed RRM2 overexpression in tamoxifen-resistant patients and was
correlated with resistant cell lines and xenograft tumors and was also found to be
significantly associated with early tumor recurrence in patients.109 RRM2 upregulation
has been reported to induce chemoresistance to cisplatin and fluorouracil (5-FU) through
activation of the epidermal growth factor receptor (EGFR)/AKT proliferative pathway.103
Not only is RRM2 important for chemoresistance it is also highly associated with disease
progression and proliferation. In rat hepatoma cells a 200-fold difference in RNR activity
was observed between the fast growing and slow growing cells.110 Because RRM2 is
highly associated with cell proliferation, its expression has been surveyed using the
ONCOMINE database. RRM2 was reported among the top 10% of most overexpressing
genes in 73 out of the 168 cancer types.16 During DNA damage in TP53+ cells RRM2 is
degraded and an isoform RRM2B is upregulated in response.111, 112 However, in TP53cells RRM2 is overexpressed in response to DNA damage to help provide nucleotides for
DNA repair and recovery from replication stress (Table 2-1).112, 113 RRM2 is an
important mediator of cancer progression and chemoresistance, especially to DNA
targeting agents.

RRM2B Regulation and Expression
RRM2B, although encoded by an independent gene, is an isoform of RRM2
sharing roughly 80% homology with it.114 RRM2B, in contrast to its isoform RRM2,
lacks a KEN box motif at the N-terminus and is continuously expressed throughout the
cell cycle at low levels.111 RRM2B is believed to play an essential role in DNA repair,
mitochondrial DNA (mtDNA) synthesis, and stress response.115 The regulation of
RRM2B expression demonstrates the cells’ ability to adapt and their tendency to survive.
In early G1-phase, cell exposure to stressors such as DNA damage or hypoxia, drives the
expression of RRM2B via the transcription factor TP53.116 Progressing though the cell
cycle after stress to the cell, RRM2B expression increases and reaches its highest level in
the G1/S transition. At the same time RRM2B is bound to RRM1 to provide nucleotides
for DNA synthesis and repair.73 Interestingly, even though RRM2B is regulated by TP53,
TP53 contains homozygous mutations in 50-60% of human cancers.117 Furthermore,
there are tumors with high expression of RRM2B with TP53 deficiencies and continues
to influence mitochondrial function, implicating that mitochondrial homeostasis, with
respect to RRM2B, is independent of TP53 function.118 There have been some studies
showing that RRM2B is also transcriptionally regulated via P73, a TP53 family
member.119 Other studies have shown binding of the tumor suppressor FOXO3 to the
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Table 2-1.

Comparison between RRM2 and RRM2B subunits.
Characteristic

RRM2

RRM2B

Contains Radical Tyrosine Residue

Yes

Yes

Contains Non-Heme Iron Group

Yes

Yes

Forms Complex with RRM1

Yes

Yes

Cell Cycle Regulated

Yes

No

Generates dNDPs for DNA Synthesis

Yes

No

Yes, in p53- cells

Yes, in p53+ cells

Generates Mitochondrial DNA (mtDNA)

No

Yes

Induced in Response to Cell Stress

No

Yes

Inhibitors

Yes

No

Generates dNDPs for DNA Repair
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RRM2B promotor activating transcription.120

RRM2B in Cancer
The deregulation of RRM2B expression has been reported in numerous cancer
types including gastric, prostate, and colon.121-123 As mentioned previously, RRM2Bs’
role in providing dNTPs for DNA repair and synthesis is exploited by cancer cells.
Alongside its catalytic role, RRM2Bs’ upregulation of P21 also further progresses cancer
due to P21 acting as a carcinogen and anti-apoptotic agent. In Akt overexpressing cancers
RRM2B may play a tumorigenic role and promote drug resistance.124 In TP53+ cells,
RRM2B is induced after DNA damage takes place. Paradoxically, DNA damage is
believed to take place within a few hours of the damage occurring, however RRM2B
induction takes longer.125 Even though they perform similar enzymatic functions, little is
known about RRM2B compared to RRM2.

Drug Resistance in Cancer
Resistance to cancer therapy, especially in the case of pediatric cancers, regarding
chemotherapies and radiation therapy has been studied for many decades. Unfortunately,
as novel chemotherapeutics have been discovered and tested, such as tyrosine kinase
inhibitors, monoclonal antibodies, and immune-oncology approaches have resulted in
new more drug resistance mechanisms. These mechanisms for drug resistance can
include molecular changes at the intracellular, transcellular, and intercellular levels as
well as effects on genetics, epigenetics, transcriptional and translational activity in the
cells. I will cover some such mechanisms below.

Drug Resistance Through Metabolism
In contrast to adult cancers, particularly carcinomas that harbor more gene
mutations and activated oncogenes, pediatric cancers are genetically “quiet”.126 However,
there are genetic mutations that do occur that specifically affect drug resistance.
Cytochrome P450 (CYP) proteins are involved in drug metabolism for numerous
chemotherapeutic agents that work on agents called prodrugs that must be metabolized
before they begin to take effect. One such mechanism of resistance is genetic variations
in these CYP proteins that can cause hypometabolism of these agents and diminish their
efficacy.127-129 These single nucleotide polymorphisms (SNPs) can also increase CYP
protein activity therefore increasing drug metabolism.127 Other involved proteins include
glutathione s-transferases (GSTs), thiopurine methyltransferase (TPMT),
methylenetetrahydrofolate reductase, and UDP glucuronosyltransferase 1 family member,
polypeptide A1. Variations in these proteins have been shown to affect drug metabolism
in many cancers including osteosarcoma,130, 131 medulloblastoma,132 neuroblastoma,133
acute lymphoblastic leukemia (ALL),134 and HB.135
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Drug Efflux or Influx
A major class of proteins that control cellular influx and efflux of molecules are
ATP binding cassette (ABC) proteins. These proteins act as pumps by directly binding to
ATP and using direct energy conversion to expel molecules in or out of the cell. One of
the ABC proteins, multidrug resistance protein 1 (MDR1) has been shown to be
overexpressed in pediatric solid tumors and leukemias and is correlated with drug
resistance and poor survival.136, 137 Other ABC family members such as MRP1, MRP2,
and ABCB1 have also been implicated in pediatric cancer drug resistance.138, 139 MRP2
has been shown to be highly expressed in HB tumors and its expression shows a reverse
correlation with cisplatin resistance, the most common drug used in the treatment for
HB.140 These proteins can be overexpressed in tumors usually through another oncogenic
pathway such as MYCN amplification in neuroblastoma,141 or MDK expression in
ALL.142 ABC proteins can also have germline or somatic mutations that increase their
enzymatic activity, which decreases drug exposure to the cells and increases
resistance.143, 144
Absorption of chemotherapeutic agents into the cell is equally as important. Some
cytotoxic agents are only able to enter the cell via direction of high concentration
gradients that occur only through active transport and change in expression or activity of
these transports can cause drug resistance.145 One such mechanism is in the case of
methotrexate resistance which is usually caused by a gene mutation in human folate
carrier (hRFC) in ALL patients. This mutation in the transporter reduces the tendency of
the drug to bind to the protein.146

Manipulation of DNA Damage Response
One of the hallmarks of cancer is its uncontrolled proliferation, therefore, many
chemotherapies are designed to target DNA synthesis which is important for replication.
Targeting DNA synthesis leads to activation of TP53, CHEK1, CHEK2, and other DNA
response pathways. TP53, which acts as a tumor suppressor and controls many pathways
in the cell in response to stress as well as DNA damage repair pathways is commonly
mutated in more than 5% of all pediatric cancers.126 Silencing of this protein, either by
somatic mutations or epigenetic regulation has been associated with increased rates of
relapse as well as worse prognosis upon diagnosis.147, 148 Another method for suppression
of TP53 is by increased activity of its regulators such as MYCN and MYC either by
amplification, translocation or epigenetic-driven overexpression. MYC amplification has
also been shown to be associated with RRM2B amplification due to its close proximity
on chromosome 8. Amplification of RRM2B is correlated with worse prognosis in some
cancers including breast.149 MYC promotes MDM2 activation which ubiquitinates TP53
leading to its degradation. Other components of DNA repair pathways have also been
shown to have mutations in some pediatric cancers such as ATM, ATR, PTEN, and
CHEK1, and are associated with a worse prognosis.150-152
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Suppression of Apoptosis
Apoptosis is the controlled death of the cell which is normal to an organism’s
growth and development. Apoptosis can be induced by a number of different
mechanisms, one of which is through the activation of TP53 following DNA damage.
TP53 promotes the expression of numerous pro-apoptotic genes including BCL2 family
members, NOXA, and PUMA. These proteins translocate to the mitochondria where they
bind to other BCL2 family members and release pro-apoptotic proteins BID, BIM, BAK,
and BAX which cause the release of cytochrome C and the activation of caspase cleavage
which leads to apoptosis. Alteration of this pathway via changes in BCL2 family member
proteins is common in childhood cancers. The overexpression of anti-apoptotic BCL2,
BCL2L1, and MCL2 driven by increased signal transduction153, alternative splicing154, or
epigenetic dysregulation155, leads to sequestering of their pro-apoptotic counterpart and a
decrease in apoptosis. As mentioned previously, mutations in TP53 are quite common
and these mutations can lead to an impaired binding to DNA and a decrease in the
expression of pro-apoptotic BCL2 family members upon DNA damage.

Treatment-induced Resistance
Cancer cells are also able to respond to chemotherapy treatments which adds
another layer of complexity to their treatment. Targeted therapies, using small molecule
inhibitors or monoclonal antibodies have been designed over the last 20 years and have
proved to be less toxic than conventional chemotherapy that targets all proliferating cells.
However, since the introduction of these drugs, unique drug resistance mechanisms have
developed in response. One such example is the use of mTOR inhibitors like sirolimus,
everolimus, and temsirolimus which target the mTOR/PI3K/AKT pathway that is over
activated in numerous cancers.156-159 Even though these drugs showed some benefits
specifically in combination therapy, tumors were found to develop a gain of function
point mutation in mTOR which made it unresponsive to first- and second-generation
inhibitors160. Other tumors were found to have overcome mTOR inhibition by
upregulating other members of the AKT pathway like MYC161 or IDO1.162 Another
instance of this is treatment induced resistance is with the fusion protein BCR-ABL. The
use of imatinib for the treatment of BCR-ABL fusion-positive chronic myelogenous
leukemia made significant improvements for the overall survival of this disease.163
However, tumors treated with imatinib have developed resistance in some cases by
selecting a population of cells that are unresponsive to the original drug.164, 165 The use of
monoclonal antibodies has been quite advantageous in the treatment of pediatric
tumors.166, 167 One mechanism of resistance to drugs is loss of expression of the target
antigen such as CD20 or CD30 in lymphomas.168, 169 In the case of some drugs, tumors
have also been shown to upregulate ABC proteins in response to treatment which results
in higher expression during therapy or if there is recurrence of the tumor and leads to
increased drug efflux out of the cell.170 Finally, in the case of HB, treatment with cisplatin
has been shown to cause mutations in tumors treated prior to resection due the adducts
generated on the DNA.171, 172 These mutations appeared in drug resistance and relapsed
cases and were commonly in genes associated with inhibition of apoptosis (BIRC5),
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DNA repair (BRCA1, RAD54L, and EXO1), or other genes associated with cancer (BRAF
and NOTCH1).172 All this together shows that there are many unique ways for cancer
cells to develop chemotherapeutic resistance and more research needs to be done on
resistance mechanisms.

Cancer Cell Plasticity
A unique characteristic of cancer cells is their plasticity, the ability to shift
between a differentiated state with limited tumorigenic potential and an undifferentiated
state or cancer stem cell like state, which is responsible for tumor growth.170 One of the
aspects of this cell plasticity is epithelial-mesenchymal transition (EMT) which
transitions differentiated epithelial cells into a more mobile ECM-secreting mesenchymal
cell. EMT has also been associated with chemotherapy resistance in tumors as well, for
example, EMT related genes are highly expressed in breast cancer and have been
associated with resistance to EGFR and PI3K inhibitors in NSCLC.173, 174 The HB cell
line HepG2 has been reported to have high expression of the transcription factor TWIST
which is known to induce EMT. Inhibition of the TWIST protein was able to sensitize
cells to cisplatin treatment.175

Targeting RNR
Due to RNRs’ essential role in DNA synthesis and cell replication it has been a
target for chemotherapy for some time. There are two current methods for targeting RNR.
The first is targeting RRM1 using nucleoside analogs because it contains the allosteric
binding sites as well as forms half of the binding pocket with RRM2. The second is using
redox active metal chelators that specifically target the non-heme iron group in RRM2
that is essential for its catalytic function mentioned above. Some siRNA inhibitors have
been developed for RRM2 and RRM2B but need further clinical validation to determine
their efficacy.

RRM1 Inhibitors
One of the first nucleoside analogs to be developed and approved for clinical use
was gemcitabine which is still used as a frontline therapy for several tumors.176
Gemcitabine’s active form (F2CDP) forms an irreversible covalent bond between RRM1
and the sugar of F2CDP.177 Interestingly F2CDP cannot fully inactivate its target unless
RRM1 binds to RRM2 or RRM2B to form the holocomplex. Only the complex forms the
site to which F2CDP binds (Figure 2-5).
Another group of clinically successful nucleoside prodrugs are clofarabine,
cytarabine, nelarabine, azacytidine, decitabine, cladribine, and fludarabine. These
nucleoside prodrugs are used to treat hematological malignancies178 and although the
metabolites for these compounds are believed to target RRM1, this process has only been
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Figure 2-5. Schematic representation of RRM1 inhibition.
Nucleoside analogs clorfarabine and gemcitabine bind to RRM1 in the enzymatic pocket,
preventing other nucleotides from being generated for DNA synthesis and repair. Created
with BioRender.com.
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elucidated for clofarabine.179 Tri-phosphorylated clofarabine (ClFTP) is the most
abundant metabolite of clofarabine and it was originally thought to be the only metabolite
that inhibited RRM1, binding in a similar way as dATP.178 However, after further
investigation it was discovered that the dephosphorylated metabolite also inhibits RRM1.
CIFTP binds reversibly to RRM1 and initial treatment shows almost complete inhibitions
of the enzyme activity but after prolonged exposure the RNR activity recovers to about
50%. The diphosphate form binds to the same location as F2CDP mentioned previously,
however it does not covalently bind and can be reversed.179 Even though nucleoside
analogs have been successful in the treatment of cancer, they have their drawbacks as
well. They are prodrugs that are dependent on other enzymes to gain activity.178
Furthermore, only specific metabolites have inhibitory effects, and a steady state
equilibrium may prevail that diminishes the inhibitory effect of the drug or possibly
increases its toxcity.180

RRM2 Inhibitors
RRM2 has been targeted more by chemotherapy than RRM1 since it is more cell cycle
regulated and has significantly higher expression during the G1/S phase in replicating
cells. Most RRM2 inhibitors attempt to target the non-heme iron tyrosine radical essential
for its function using radical scavengers or iron chelators.181 Hydroxyurea (Figure 2-6A),
which has been used for a long time in the treatment of cancer, specifically in
leukemia182, 183 does both. Hydroxyurea is not specific to RRM2 however, it does
interfere and bind with other metalloenzymes such as carbonic anhydrase or matrix
metalloproteinases.184 The structure of hydroxyurea has been used to derive other RRM2
inhibitors such as didox which has been shown to be effective in resistant renal cell
carcinoma105 and help prevent tamoxifen resistance in breast cancer.185
Another RRM2 specific inhibitor is triapine (Figure 2-6A) which has been used in
clinical trials for solid tumors such as head and neck squamous cell carcinoma.186
Triapine is a thiosemicarbazone that even shows some efficacy against tumors that are
resistant to hydroxyurea187. The initial mechanism of action for triapine was thought to
inhibit RRM2 through iron chelation at its active site.188 However, the mechanism was
later thought to be incorrect when a metal bound form of triapine (Fe(II)-(3AP)), was
able to generate reactive oxygen species (ROS) that inhibited RRM2 under aerobic
conditions.189 Recent studies have shown that the Fe(II)-(3AP) form of triapine is the
active form and inhibits RRM2 at a faster rate via the production of ROS rather than by
iron chelation.190
In 2013 a new compound called COH29 (Figure 2-6B) was developed to target a novel
binding site on RRM2 near the C-terminal tail. Initial studies with this compound showed
that it was blocking the assembly of RRM1 and RRM2 holocomplex and it was able to
overcome hydroxyurea and gemcitabine resistance in some tumor cells.191 It is still a
relatively novel compound so more studies into its mechanism of action are needed.
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Figure 2-6. Schematic representation of RRM2 inhibition.
(A) Iron chelators triapine and hydroxyurea targeting the non-heme iron group of RRM2.
(B) COH29 binds to RRM2 preventing the RNR complex formation. (C) MK1775
inhibits Wee1 leading to increased activation of CDK1/2. This leads to RRM2
ubiquitination and degradation via the proteasome. Created with BioRender.com.
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Besides targeting RRM2 directly, another method of RRM2 inhibition is by
targeting upstream regulators. One such drug, MK1775 (Figure 2-6C), works in this
manner. MK1775 is a Wee1 inhibitor and effects RRM2 regulation. Inhibition of Wee1
leads to activation of the cyclin dependent kinase (CDK2) which targets RRM2 for
ubiquitination and subsequent degradation via the proteosome. MK1775 has shown
promising tumor inhibition in combination with other small molecule inhibitors in some
cancers such as Ewing sarcoma.192

RRM2B Inhibitors
Due to RRM2B’s low level of expression in cells no specific inhibitors have been
developed for it. However, as mentioned before RRM2B shares 80% homology with
RRM2 and the iron contents of RRM2B and RRM2 were found to be almost identical.114
Iron chelators that were known to target RRM2 were also tested against RRM2B to see if
they could inhibit activity. One drug, Deferoxamine (DFO) showed a 158-fold inhibition
of RRM2B over RRM2, however this was the only compound found to be effective.114
As previously mentioned, RRM2B is crucial for cell survival, so specific RRM2B
inhibitors are needed.
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CHAPTER 3.

METHODOLOGY

Mice
Animal protocols were approved by the St. Jude Animal Care and Use
Committee. All mice were maintained in the Animal Resource Center at St. Jude
Children’s Research Hospital (St. Jude). RRM2- and RRM2B- manipulated HepG2 cells
were surgically injected into the liver of two-month-old NSG (NOD scid gamma) mice
(JAX) at 5 × 104/mouse in 2 ml cold growth factor-reduced (GFR) matrigel (Corning,
Corning, New York) using a 5-ml Hamilton syringe and a 27-gauge needle (Hamilton
Company, Bonaduz, Switzerland). Animal survival curves and their median survival
were determined by the Kaplan–Meier method in GraphPad Prism 7 and significance
between median survival was determined using unpaired two-tailed students t test.

Liver Cell Isolation
Liver tissues were rinsed with ice cold PBS and minced (0.5-1mm3), then
incubated with Papain digestion solution (10U/ml Papain [Worthington]; 1mM NAC
[Sigma], 12µg/ml DNase I [Sigma] in Advanced DMEM/F12 [Gibco]) for 20–60 min at
37°C with regular shaking and pipetting. Digestion was terminated after obtaining a
homogenous cell suspension by adding cold Advance DMEM/F12. The suspension was
then filtered through a 70 m cell strainer (Corning) and centrifuged at 400×g for 5 min.
The pellet was washed twice with cold Advance DMEM/F12, followed by centrifugation
at 400×g for 5 min.

Mouse Liver Stem Cells Culture
Cells isolated from mouse liver tissues were resuspended in liver stem cell culture
medium. Advanced DMEM/F12 (Gibco) supplemented with 2% B27, 1% N2 (both from
(Gibco), 10% Pen-Strep, and 10% L-Glutamine was used as basic medium, and mixed
with 50% Wnt3A conditioned media (ATCC, CRL-2647™) supplemented with 1.25mM
N-Acetylcysteine (Sigma), 10nM Gastrin (Sigma), and growth factors, including 50ng/ml
EGF (Peprotech), 1µg/ml R-spondin1, 100ng/ml Noggin, 100ng/ml FGF-10, 50ng/ml
HGF (all from R&D), and 10mM Nicotinamide (Sigma). Cells were then seeded in
60mm culture plates (Corning) coated with growth factor-reduced Matrigel (Corning).
Cells formed liver spheroids after 3 days in culture. To passage, liver spheroids were
lifted from Matrigel using dispase (Corning), collected using a 40m cell strainer
(Corning), and dissociated into single cells using accutase (Gibco). Passaging was
performed at a 1:3 ratio once every 5–7 days.
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Ultrasound-guided Intrahepatic Cell Injection
Mice were anesthetized with 2–3% isoflurane/O2, positioned ventrally, and
secured on the heated platform. Warmed Aquasonic 100 (Parker Laboratories) coupling
gel was applied to the surface of the abdominal skin, and the right liver lobe was imaged
using a VEVO-770 High Resolution Ultrasound system (FujiFilm VisualSonics). A 22G
catheter (BD) was inserted gently through the skin perpendicular to the incident plane of
the transducer into the ultrasound field of view. The catheter needle was then removed to
leave the plastic housing for injection. 10 μl of cell suspension was drawn using a precooled 25μl Hamilton syringe with a 27G needle. The needle was then placed in the
injector housing and guided into the right liver lobe within the US field of view using
stereotactic controls. Cells were injected and the needle was retained in situ for 1 min to
allow the implant to solidify. The needle was then slowly removed, followed by the
gentle removal of the catheter. The animal was then removed from the bed and monitored
until recovery.

PDX Establishment and In Vivo Studies
PDX were established and efficacy studies were performed as described
previously.193, 194 The in vivo studies were performed at XenTech. Fragments from HB214 PDX were engrafted in the interscapular region of 6–12-week-old female athymic
nude mice (Athymic NudeFoxn1nu, ENVIGO, Gannat, France). After latency period,
mice bearing tumor between 62 and 256 mm3 were randomly assigned to each treatment
arm according to their tumor volume to obtain homogenous mean and median tumor
volume in each arm. The control group was not treated during all the course of the
experiment. Irinotecan HCl trihydrate (MedChem, Monmouth Junction, New Jersey)
(dissolved in 99% NaCl 0.9%; 2.5mg/kg) was administrated intraperitoneally daily for
five consecutive days per week for three weeks or first for three consecutive days then
one day off followed by five consecutive days per week for two weeks. MK-1775
(MedChem) (dissolved in 0.5% Methylcellulose; 60mg/kg) was administrated orally
three time per week for three or four weeks. Treatments were stopped prematurely if
toxicity was observed. Tumor volumes were measured two to three time per week
depending on the tumor growth. Tumors diameters (length and width) are measured with
a caliper (digimatic Solaire, IP67) and tumor volume (TV) is calculated using the formula
TV (mm3) = [length (mm) x width (mm)2]/2, where the length and the width are the
longest and the shortest diameters of the tumor measured perpendicularly, respectively.
All animals were weighed at tumor measurement time and were observed every day for
physical, behavior, and clinical signs.

Immunohistochemistry
Liver and tumor tissues were fixed in neutral buffered formalin for one day at
room temperature and submitted to HistoWiz Inc. (Brooklyn, NY) for paraffin
processing and embedding. Paraffin sections were cut at 4 µm and analyzed using
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direct fluorescence microscopy, H&E staining, IHC, and RNAscope.195. IHC protocol
is as follows, using a Tissue-Tek II slide staining set, slides were immersed in Xylene
(Fisher Scientific, X3S-4) for 5 mins, Xylene for 5 mins, 100% ethanol for 5 mins, 95%
ethanol for 5 mins, 70% ethanol for 5 mins, and finally 50% ethanol for 5 mins. Slides
were then steamed in a Classis Prestige Medical autoclave containing IHC antigen
retrieval solution (Invitrogen, 00-4955-58). After slides are allowed to cool to room
temp overnight, slides are immersed in water for 5 mins x 2, 1% PBS with 0.1% Triton
X100 (Sigma Aldrich, 93443-100ml) for 5 mins, 3% hydrogen peroxide (Honeywell
Fluka, Seelze, Germany) for 5 mins, water for 5 mins x 2, and finally in 1% PBS with
0.1% Triton x100 for 5 mins. Antibodies were stained using M.O.M. kit (Vector
Laboratories Inc, BMK-2202) and Vectastain Elite ABC HRP kit (Vector Laboratories
Inc, PK-6100). Antibodies used included anti-Ki67 (Abcam, Cambridge, MA, USA,
ab16667, 1:200). Slides are washed in 1% PBS with 0.1% Triton X100 for 5 mins x 2.
and stained with hematoxylin for 5-45 seconds (Vector Labratories Inc, H3404). Slides
are then washed with water for 5 mins x 2 and mounting is done using 50% ethanol for
5 mins, 70% ethanol for 5 mins, 95% ethanol for 5 mins, 100% ethanol for 5 mins,
xylene for 5 mins, and finally a second xylene for 5 mins. Slides are then mounted with
Permount (Fisher Scientific, SP15-100).

RNAscope Staining
RNAscope in situ hybridization of RRM2 and RRM2B mRNA transcripts was
performed according to the manufacturer's protocol (Advanced Cell Diagnostics,
Hayward, CA, USA).

Immunoblotting Assay
Cells were lysed using radio-immunoprecipitation assay (RIPA) buffer (Thermo
Fisher Scientific, Waltham, MA, Cat #89900) supplemented with protease and
phosphatase inhibitors (Thermo Fisher Scientific, #78440) and 0.5M
Ethylenediaminetetraacetic acid (EDTA) (#78440, Thermo Fisher Scientific). Lysates
were centrifuged at 14,000 rpm for 15 minutes at 4°C. Protein concentrations were
determined using PierceTM BCA Protein Assay Kit reagent (Thermo Fisher Scientific,
#23227). 15μg of protein were loaded and separated by electrophoresis on NuPAGETM
4 to 12% Bis-Tris, 1.0, Protein gel (Invitrogen, Waltham, MA). Antibodies were used
according to the manufacturers recommended conditions anti-p53R2 + RRM2 antibody
(abcam, Cambridge, United Kingdom, ab209995, 1:10000), anti-RRM2 antibody
(abcam, ab172476, 1:5000). Molecular weight marker EZ-RunTM prestained protein
ladder (Thermo Fisher Scientific, BP3603500,) was used to confirm the expected size
of the proteins of interest. Immunoblots were developed with SuperSignalTM West
Femto Maximum Sensitivity Substrate (# 34095, Thermo Fisher Scientific) and imaged
on a LiCor ODYSSEY Fc (LiCor Inc. Lincoln, NE, Model # 2800). Equal protein
loading was confirmed using anti-vinculin antibody (abcam, ab219649, 1:5000).
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Cell Growth Assay
5 x 104 Cells were seeded in a 6-well plate in triplicate (Day 0) and allowed 24
hours to settle and adhere. After 24 hours plates were imaged on a Lionheart FX imager
(Biotek) using a protocol enabling us to image the exact same location on the plates on
days 1 through 5 to monitor growth. Image J was used to measure cell surface area and
determine fold change. Experiment was repeated two more times and significance was
determined using unpaired two-tailed students t test.

CTG Viability Assay
For cell viability a Cell Titer Glo (CTG) assay was used, HepG2 (1,500
cells/well) was seeded on a 384 well plate in 30 ml and incubated for 24 hours. Drug
treated cells and their respective controls were incubated for 72hours. For quantification,
CellTiter-Glo 2.0 (#G9243 Promega) was added to each well in a 1:1 v/v ratio. Plates
were then covered to keep from light and incubated at RT on an orbital shaker at 150
RPM for 30mins. After the incubation, plate was read on a synergy H4 plate reader for
luminescence. Dose effect curves for each drug were calculated using Prism software,
version 9 (GraphPad). For drug combinations, responses were analyzed using
SynergyFinder2.0196. Drugs used were cisplatin (#479036-5G Sigma Aldrich),
gemcitabine (#AC456890010 Fisher Scientific), vincristine (#AAJ60907MA Fisher
Scientific). triapine (#50-136-4826 Fisher Scientific), MK1775 (#M4102 LKT
laboratories, Saint Paul, Minnesota), doxorubicin (#BP25161 Fisher Scientific), sorafenib
(#NC0749948 Fisher Scientific), SN-38 (#S4908-50MG Selleck Chemicals, Harris
County, Texas), deferoxamine mesylate (#AC461770010, Acros Organics, Geel,
Belgium), KU60019 (#S1570, Selleck Chemicals). All concentrations were seeded in
triplicate and the experiment was repeated two more times. Significance was determined
using the Extra Sum of Squares f test.

RRM2 Knockdown
Lentivirus particles were added to HepG2 at a MOI of 3 (Dharmacon
V3SH7669-226296450 (RRM2) VSC6544 (GAPDH), and VSC6572 (Scramble)). Cells
were selected using puromycin at a concentration of 2 µg/mL until cells in control wells
were dead. A doxycycline dose curve was performed to determine optimal dose of
doxycycline without loss of cell viability. 500 ng/ml of doxycycline was the optimal
dose, and all future experiments were performed using that concentration. Target
sequence for RRM2 was (5’ – AGAACCCATTTGACTTTAT – 3’).

RRM2 and RRM2B Knockout by CRISPR/Cas9
RRM2BKO cells were generated using CRISPR/Cas9 technology. Briefly, 4 ×
10 HepG2 cells were transiently transfected with pre-complexed ribonuclear proteins
5
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(RNPs) consisting of 100 pmol of chemically modified sgRNA 5’ –
UUCAUUUACAAUUCCAUCAC- 3’, Synthego, 35 pmol of Cas9 protein (St. Jude
Protein Production Core), and 500 ng of pMaxGFP (Lonza) via nucleofection (Lonza,
4D-Nucleofector™ X-unit) using solution P3 and program EN-158 (HB214) or CA138 (HepG2) in a 20 μL cuvette according to the manufacturer’s recommended
protocol. Five days post nucleofection, cells were single-cell sorted by FACs to enrich
for transfected GFP+ cells, clonally selected, and verified for the desired targeted
modification (out-of-frame indels) via targeted deep sequencing using gene specific
primers with partial Illumina adapter overhangs (F– 5’
TCCATAGTTTACTGGTAGTGGGAT-3’ and R – 5’
AGACATCTTGTCTTTGGCTGAATTT-3’, overhangs not shown) as previously
described.197 Briefly, approximately 1 × 104 cells were lysed and used to generate
amplicons flanking the gRNA cut site with partial Illumina adapters in PCR #1. During
PCR #2 amplicons were indexed and pooled with other amplicons to create sequence
diversity. Additionally, 10% PhiX Sequencing Control V3 (Illumina) was added prior
to running the sample on an Miseq Sequencer System (Illumina) to generate paired 2 X
250 bp reads. Samples were demultiplexed using index sequences and fastq files were
generated. NGS analysis of clones was performed using CRIS.py.198 Knockout clones
were identified as clones containing only out-of-frame indels. RRM2KO was attempted
in HepG2 RRM2BOE cells using the same protocol (sgRNA 5’ –
CGGUCUUGCUGGCCAGGA – 3’). Final clones or pools were authenticated using
the PowerPlex® Fusion System (Promega) performed at the Hartwell Center for
Biotechnology at St. Jude Children’s Research Hospital. Final clones tested negative
for mycoplasma by the MycoAlertTM Plus Mycoplasma Detection Kit (Lonza).

RRM1 Co-Immunoprecipitation Assay
Protein extracts were prepared as previously described.199 Protein extracts (50
μg) were loaded in 4 %-20 % gradient gels (Bio-Rad, Hercules, CA) and transferred to
nitrocellulose membranes (Bio-Rad). RRM1 was immunoprecipitated from whole cell
extracts using an improved Trueblot (Rockland Immunochemical, Limerick, PA)
protocol as previously described199 with polyclonal antibodies (abcam, ab13714), and
the presence of RRM2 and RRM2B in the precipitated fraction was examined by
immunoblotting with the same antibodies mentioned above (abcam, ab209995).

Clonogenic Assay
HepG2 or HB214 (5 × 105 /well) cells were seeded in a 6-well plate and
incubated for 24 hours. The medium was replaced with medium containing treatment in
the concentration stated in the different experiments and the respective controls. After
incubation for 72hours cells were trypsonized and seeded (1×104/well) in a new 6-well
plate in duplicate with fresh medium and allowed to incubate for 14 days. On day 14
wells were washed with PBS and incubated with 6% glutaraldehyde (#BP2547-1
Fisher) and 0.05% w/v crystal violet (#C581-25 Fisher) for 30 minutes. After
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incubation wells were washed with ddH2O and allowed to dry. Plates were then imaged
on an Epsom V850 scanner and Image J was used to determine the cell area.
Experiment was repeated two more times and significance was determined using
unpaired two-tailed students t test.

RRM2 and RRM2B Overexpression
pLVX-IRES-tdTomato-FlagAkt1 vector was obtained from Addgene (#64831)
and flagakt1 was removed creating pLVX-IRES-tdTomato (RTD) control vector. RRM2
and RRM2B fragments were generated using HepG2 endogenous DNA and PCR
amplified using Clone Amp HiFi (Takara #639298). Fragments were purified on a DNA
gel and extracted (Qiagen #28706), fragments were then inserted into the RTD control
vector creating pLVX-IRES-tdTomato-RRM2 and RRM2B respectively. Plasmids were
expressed in E. Coli DH5α competent cells (NEB #C2987H) and purified (Qiagen
#12165). Purified plasmid was sent for sanger sequencing and the verified plasmids were
sent to the vector core for viral packaging. HepG2 cells were transduced with lentiviral
particles at a M.O.I of 3 and the FASC sorted for tdTomato expression.

Quantitative RT-PCR
The total RNA in cells were extracted using RNeasy® Mini Kit (#74106
Qiagen) and the concentration and purity of the RNA were measured by nanodrop
spectrometer. SuperScript® III First-Strand Synthesis SuperMix for qRT-PCR (#11752250 Invitrogen) was used for cDNA synthesis from 1 μg total RNA. FastStart Universal
SYBR® Green Master (ROX) (#0491385001 Roche, Mannheim, Germany) was used
to perform the quantitative PCR assay on the 7900HT Sequence Detection System
(Applied Biosystems, Carlsbad, CA, USA). The results were analyzed using 2-ΔΔCt
Method, with ATCB as the internal reference gene. Experiments were performed in
triplicate and repeated two more times. Significance was determined using unpaired
two-tailed students t test. The primers were as follows: RRM2:
CTGGAAGGAAAGACTAACTTCTT (Forward), CGTGAAGTCAGCATCCAAGG
(Reverse); RRM2B: CCTGCGATGGATAGCAGATAG (Forward),
GCCAGAATATAGCAGCAAAAGATC (Reverse); ATCB:
GTTGTCGACGACCAGCG (Forward), GCACAGAGCCTCGCCTT (Reverse).

Nucleotide Detection via Targeted LC/MS
Cells were cultured in 6-well plates to ~85% confluence and washed with 2 mL
ice cold 1X Phosphate-Buffered Saline (PBS). The cells were then harvested in 300 µL
freezing 80% acetonitrile (v/v) into 1.5 mL tubes and lysed by Bullet Blender (Next
Advance) at 4 °C followed by centrifugation at 21,000 x g for 5 min at 4 °C. The
supernatant was dried by speedvac and reconstituted in 7.5 µL of 66% acetonitrile and
2 µL was separated by a ZIC‐HILIC column (150 × 2.1 mm, EMD Millipore) coupled
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with a Q Exactive HF Orbitrap MS (Thermo Fisher) in negative detection mode.
Metabolites were eluted within a 45 min gradient (buffer A: 10mM ammonium acetate
in 90% acetonitrile, pH=8; buffer B: 10 mM ammonium acetate in 100% H2O, pH=8).
The MS was operated by a full scan method followed by targeted selected ion
monitoring and data-dependent MS/MS (tSIM/dd-MS2). MS settings included full scan
(120,000 resolution, 350-550 m/z, 3 x 106 AGC and 50 ms maximal ion time), tSIM
scan (120,000 resolution, 1 x 105 AGC, 4 m/z isolation window and 50 ms maximal
ion time) and data-dependent MS2 scan (30,000 resolution, 2 x 105 AGC, ~50 ms
maximal ion time, HCD, Stepped NCE (50, 100, 150), and 10 s dynamic exclusion).
Data were quantified using Xcalibur software (Thermo Fisher Scientific) and
normalized by cell numbers. Ribonucleotide and deoxyribonucleotides were validated
by authentic standards.

RNA Extraction, Sequencing, and Data Analysis
The total RNA was extracted from HepG2 cells at different conditions using
RNeasy® Mini Kit (#74106 Qiagen) following the manufacturer’s protocol. The TruSeq
Stranded mRNA LTSample Prep Kit (Illumina) was used for library preparation, and
PE-100 sequencing was performed using an Illumina HiSeq X Ten instrument
(Illumina). All relevant sequencing data will be available at GEO. The adapters used in
library preparation were identified by FastQC (v-0.11.5)
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and trimmed from the
raw reads by cutadapt (v-1.13) (https://doi.org/10.14806/ej.17.1.200) with the default
parameters. RSEM (v-1.3.0)200, coupled with Bowtie2 (v-2.2.9)201, were used to
quantify the expression of genes based on the reference genome hg38 (GRCh38) with
gene annotation from GENCODE (release v32). The Transcripts Per Million (TPM)
values were extracted and further transformed to log2(TPM+0.1) for subsequent
analysis. The differential expression analysis was conducted using limma R package (v3.42.2).202 The gene set enrichment analysis (GSEA) was performed by the fgsea R
package (v-1.12.0) (https://doi.org/10.1101/060012) with MSigDB dataset (v-6.1)203
and visualized by NetBID software (v-2.0.2). To evaluate the accuracy of gene
expression quantification, Salmon (v0.9.1) was employed to calculate the TPM values
of genes. The Spearman correlation coefficient and p-value were calculated from the
TPM values of genes co-identified by RSEM and Salmon using the stats R package
(v3.6.1).

Hub Gene Identification of RRM2 and RRM2B in HB and HCC
We used a scalable software for gene regulatory network reverse-engineering
from big data, SJARACNe (v-0.1.0)204, to reconstruct context-dependent signaling
interactomes from the gene expression profiles of 46 HB patient samples collected from
GSE75271205 and 374 HCC patient samples collected from TCGA-LIHC206, respectively.
The parameters of the algorithm were configured as follows: p value threshold p = 1e-7,
data processing inequality (DPI) tolerance € = 0, and number of bootstraps (NB) = 200.
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We used the adaptive partitioning algorithm for mutual information estimation. Both the
upstream and downstream first neighbors of RRM2 or RRM2B were extracted and
considered as the hub genes in each context.

Gene Set Enrichment Analysis of RRM2 and RRM2B Hub Genes
To identify the cellular processes regulated by RRM2 and RRM2B, we first
applied a hypergeometric distribution method for the gene set enrichment analysis
using the “funcEnrich.Fisher” function from the R package NetBID (v-2.0.2).207 Only
the HALLMARK and KEGG gene sets from the MSigDB database (v-6.1)203 were
used. The p values of the enrichment analysis of both HB and HCC patient cohorts
were further combined with the Stouffer method embedded in the
“combinePvalVector” function from NetBID. We then picked the top 10 most
significantly enriched gene sets by the hub genes of RRM2 and RRM2B respectively
and introduced the Gene Set Enrichment Analysis (GSEA) on both HB and HCC
primary patient samples and HepG2 cell lines of different conditions. The differential
expression analysis of primary patient samples was performed between
RRM2/RRM2B-high and -low which were defined as the top 1/3 and bottom 1/3 in
each cohort. The visualization was completed by ggplot2 (v-3.3.4, Wickham H
(2016). ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York. ISBN
978-3-319-24277-4 (https://ggplot2.tidyverse.org/).

Statistical Analysis
Experimental data were analyzed using the unpaired two-tailed Students t test.
Drug response curves were analyzed with GraphPad software using the Extra Sum of
Squares f test. Kaplan Meier curves for survival were analyzed with GraphPad using
the log-rank test.
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CHAPTER 4. RIBONUCLEOTIDE REDUCTASE SUBUNIT SWITCHING IN
HEPATOBLASTOMA DRUG RESPONSE AND RELAPSE

Introduction
Hepatoblastoma (HB) is a rare type of primary liver cancer that only affects
very young children.208 Although accounting for only 0.5-2% of all cancer cases in
children,209 HB has the largest increase in incidence among childhood cancers in the
United States and worldwide.210 Most HB tumors are sensitive to chemotherapy and
children with HB have an excellent overall five-year survival of >80%. But for
children diagnosed with high-risk HB, this number drops to below 40% even with
multidisciplinary therapies.35 Studies in many adult solid tumors have found that tumor
cells can develop drug resistance during the course of treatment via various
mechanisms as part of their adaptation to stress conditions.211, 212 This raised an
intriguing question as to whether HB cells in high-risk tumors, with their known
cellular and molecular heterogeneity and plasticity,172 can similarly evoke a selfdefense machinery when treated by anti-cancer drugs to increase their chance of
survival.
Recent work in our lab using HB mouse and organoid models,13 patient-derived
xenografts (PDX) and primary patient samples revealed a significant upregulation of
ribonucleotide reductase (RNR) in high-risk HB. RNR is the sole enzymatic complex in
mammalian cells that converts ribonucleoside diphosphate (NDP) to deoxy-NDP
(dNDP).213 It plays a critical role in regulating the total rate of DNA synthesis during
cell division and DNA repair. 214-216 RNR is a heterodimeric tetramer composed of two
large RNR subunit M1 (RRM1) and two small RNR subunit M2 (RRM2)16. RRM2 has
the catalytic domain of RNR and is tightly cell-cycle regulated.21 Therefore, it is not
surprising that RRM2 upregulation has been found in many adult cancers.217-221 There
is another low-expressing RNR M2 subunit, RNR subunit M2B (RRM2B), which has a
lower catalytic activity than RRM2 and is not cell-cycle regulated.222 It has been found
that RRM2B can be induced in a p53-dependent manner under certain stress conditions
and becomes the dominant M2 subunit to support DNA repair.116, 223 Since there is little
known about the involvement of RNR in pediatric cancer, we decided to investigate
RNR dynamics regarding to its role in HB progression and drug response.

Results

RRM2, Not RRM2B, Is Associated with Disease Progression in HB Patients and
Promotes HB Cell Growth
We previously generated a HB mouse model by targeting a population of Prom1expressing neonatal liver progenitors with an activating Notch mutation, NICD (Notch
intercellular domain), Prominin1CreERT2; RosaNICD1/+; RosaZsG (PNR) mice.11 PNR mice
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developed frequent primary tumors in the liver but rare metastases. We then reported the
generation of multiple cancer organoid lines derived from the PNR tumors. PNR
organoid lines varied in their in vivo tumorigenicity with a subset being tumorigenic and
metastatic upon orthotopic transplantation and the others generating no tumors in vivo
(Figure 4-1A).13 To pinpoint the molecular mechanisms driving metastasis in the PNR
models, we performed a comparative RNAseq analysis of metastatic and nonmetastatic
PNR-T and PNR-O samples to identify genes associated with metastasis. The same
analysis was done for a hepatocellular carcinoma (HCC) mouse model, PPTR
(Prominin1CreERT2; Ptenflx/flx; Tp53flx/flx; RosaZsG) mice, and combined to identify genes
commonly associated with liver cancer metastasis (Figure 4-1B).11, 13 Among the top
upregulated genes in metastatic PNR and PPTR tumors and organoids was Rrm2 (Figure
4-1C, D), the catalytic M2 subunit of the ribonucleotide reductase (RNR) complex. RNR
catalyzes the formation of deoxy-ribonucleoside diphosphate (dNDP) from NDP. We
found that the expression of the other two RNR subunits, Rrm1 and the other catalytic
subunit Rrm2B, did not show consistent association with the metastatic potential of
tumors and organoids from both models (Figure 4-1C, D). We then wanted to validate
that Rrm2 and not Rrm2B was associated at the protein level in our PNR model. Due to
RRM2Bs close homology with RRM2, there are no antibodies targeting RRM2B
specifically. However, using a dual antibody that recognizes both Rrm2 and Rrm2B,
immunohistochemistry (IHC) showed a consistent increase in the number of
Rrm2/Rrm2B+ cells in metastatic tumors compared to primary tumors (Figure 4-2A). To
further validate that RRM2 was associated with HB progression and not RRM2B, we
performed an RNA in situ hybridization assay called RNAscope that allowed us to
distinguish between the two genes. Using HB PDXs, we saw a higher expression of
RRM2+ cells than RRM2B+ cells in both primary and metastatic tumors (Figure 4-2B,
b vs. c and f vs. g). Comparing HB PDXs derived from primary tumors to metastatic
tumors, the latter appeared to have a relatively higher percentage of RRM2+ cells (Figure
4-2B, b vs. f). RRM2 positivity in HB PDX tumors was well aligned with that of a cell
proliferation marker Ki67 (Figure 4-2B, d and h,), supporting the role of RRM2 in cell
proliferation. Lastly, analysis of a previously published gene expression profiles of 88
HB patient tumors205 also showed a correlation of Ki67 with RRM2 expression, not with
RRM2B expression, with both the pathologically- and molecularly-defined HB risk
groups (Figure 4-2C).
To compare the role of RRM2 and RRM2B in HB cell proliferation, we
overexpressed RRM2 and RRM2B as well as a TdTomato (TdT) empty vector in a
human HB cell line HepG2224, 225 (Figure 4-3A). To confirm that our exogenous proteins
were enzymatically active we checked the levels of free NDPs, dNDPs, and dNTPs in the
cells using targeted liquid chromatography/mass spectrometry (LC/MS). We were able to
detect high levels of all nucleotides in our overexpressing cells compared to the control
cells which were virtually undetectable for several of the nucleotides (Figure 4-3B). We
also saw that nucleotide levels were higher in RRM2-overexpressing (RRM2OE) compared
to RRM2B-overexpressing (RRM2BOE) cells correlating with the reported higher
enzymatic activity of RRM2 (Figure 4-3B). We then tested the growth rate of these cell
lines, and accordingly, saw that RRM2OE cells showed a slight increase in growth rate
compared to the TdT control cells, while no change was observed in the RRM2BOE cells
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Figure 4-1. RRM2 is upregulated in organoid transplantation model.
(A.) Schematic illustration showing the establishment of PNR genetic mouse, organoid,
and orthotopic transplantation models. (B.) Flow chart for the comparative transcriptomic
analysis of the tumors and organoids from the PNR and PPTR mouse models. (C.)
Quantitative comparison of the three RNR subunits in PNR tumor tissues and organoids
in the indicated groups. (D.) Quantitative comparison of the expression of three RNR
subunits in PPTR tumor tissues and organoids in the indicated groups. p values were
calculated by Student t test: * < 0.05; ** <0.01; *** <0.001; ****<0.0001.
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Figure 4-2. RRM2 is associated with HB disease progression.
A.) H&E (left) and RRM2/RRM2B IHC staining (right) on the serial sections of localized
and metastatic PNR tumors. Dotted lines: tumor border; arrows: colonic polyps
embedded in the tumor. All images share the same 100 μm scale bar. (B.) H&E staining
(a, e), RNAscope staining for RRM2 (b, f) and RRM2B (f, g), and Ki67 IHC staining (d,
h) on serial sections of HB PDX tumors derived from primary and metastatic patient
tumors. Al images share the same 200 μm scale bar. Insets in (b, c, f, g): higher
magnification images; scale bars, 20 μm. (C.) Expression of the three RNR subunits in
pathologically-defined (low, medium, and high) HB patient risk groups and molecularlydefined (HB1, HB3, and HB2) risk groups from a publicly available HB transcriptomics
database.205 p values were calculated by Student t test: * < 0.05; ** <0.01; *** <0.001;
****<0.0001.
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Figure 4-3. Overexpression of RRM2 and RRM2B in HepG2 cells.
(A.) Quantitative RT-PCR and immunoblotting of RRM2 and RRM2B in the indicated
HepG2 cells. (B.) Quantitative analysis of nucleotide levels in TdT, RRM2OE, and
RRM2BOE HepG2 cells using targeted LC/MS. p values were calculated by Student t test:
* < 0.05; ** <0.01; *** <0.001; ****<0.0001.
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(Figure 4-4A). Interestingly, when TdT, RRM2OE and RRM2BOE HepG2 cells were
orthotopically transplanted into NOD scid gamma (NSG) mice, we saw a slight decrease
in survival in the RRM2BOE cells but not in the RRM2OE cells (Figure 4-4B). This could
partially be explained by the variability from orthotopic cell injections as the significance
was not great. The minimal increase in growth observed in the RRM2OE cells could be
due to RRM2 already being highly expressed in HepG2 cells. To further see if RRM2 or
RRM2B influenced cell growth we attempted to knockout (KO) the two genes. DepMap
Portal shows RRM2 is an essential gene and its KO leads to the death of all cancer cell
lines tested. However, we tested a doxycycline-inducible shRNA targeting RRM2. We
were able to see a clear dose-dependent knockdown of RRM2 which led to a significant
decrease in cell growth with compared to the different controls (Figure 4-4C, D). With
the help of Dr. Shondra Miller and Baranda Hansen, we were able to successfully KO
RRM2B in two HepG2 cells clones that were grown from single cell selection using
CRISPR/Cas9 (Figure 4-4E). KO of RRM2B showed no change in cell growth in HepG2
cells (Figure 4-4F). When these KO cells were orthotopically transplanted into NSG
mice there was no change in survival in either of the two cell lines (Figure 4-4G). Our
nucleotide analysis results showed that RRM2BOE cells were able to produce sufficient
levels more so than the control TdT cells. We attempted to KO RRM2 in the RRM2BOE
cells to see if the subunits were able to compensate for each other. However, this failed as
we noticed an unusual bias towards in-frame indels that persisted in culture (Figure
4-5A-C). A wildtype copy of RRM2 was also retained by all cells that survived long-term
cultivation. Overall, these results indicate that RRM2 is the dominant RNR M2 subunit
supporting HB cell growth. Although highly homologous in protein sequences, RRM2
and RRM2B likely play different roles in HB cells.

Drug Treatment Suppresses RRM2 but Induces RRM2B in HB Cells In Vitro and
In Vivo
Upregulation of RRM2 has been reported in many adult solid tumors. Inhibitors
have been developed which, however, only showed suboptimal benefits to adult
patients with advanced solid tumors.226-228 Since pediatric cancer is generally more
sensitive to treatment than adult cancer, we decided to test two agents that have shown
to inhibit RRM2 either directly or an upstream regulator, triapine229 and MK177522
respectively. We tested two HB cell lines HepG2 and HB214, a previously reported HB
PDX model,230 that generated tumors with faithful HB histopathology when
transplanted into NSG mouse liver.195 Triapine and MK1775 showed comparable
efficacies to other standard liver cancer chemotherapies including cisplatin,
gemcitabine, vincristine, and SN38, an active form of irinotecan231 (Figure 4-6A).
When examining the response of the RNR subunits to drug treatment, we noticed that
all the drugs tested led to a significant reduction in the RRM2 protein levels in both cell
lines. However, interestingly, they also led to a significant increase in the RRM2B
protein levels (Figure 4-6B). RNAseq profiling of cis-treated HepG2 cells showed that
these drug-induced changes in RRM2 and RRM2B happened at the mRNA level as
well (Figure 4-6C). We wanted to verify that the switching of the two subunits were
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Figure 4-4. RRM2, not RRM2B, is associated with cell growth in vitro.
(A.) Growth curves of TdT, RRM2OE, and RRM2BOE HepG2 cells. (B.) Kaplan Meier
curves of TdT, RRM2OE, and RRM2BOE cells orthotopically transplanted into NSG mice.
(C.) RRM2 and RRM2B immunoblotting showing a dose-dependent knockdown of
RRM2 in HepG2 cells. GAPDH shRNA was used as the control. (D.) Growth curves of
the indicated HepG2 cells treated with 500 ng doxycycline (dox). (E.) Immunoblot
showing knockout of RRM2B in two HepG2 cell lines. (F.) Growth curves of HepG2
(Ctrl), RRM2BKO1, and RRM2BKO2 cells. (G.) Kaplan Meier curves of HepG2,
RRM2BKO1, and RRM2BKO2 cells orthotopically transplanted into NSG mice. p values
were calculated by Student t test or Log Rank test for survival curves: * < 0.05; ** <0.01;
*** <0.001; ****<0.0001.

44

45

Figure 4-5. RRM2 is essential in HepG2 cells.
(A.) The position and sequence of RRM2 guide RNA. (B.) Indels after attempted
knockout of RRM2 in HepG2 RRM2BOE cells. (C.) Quantitative analysis of RRM2 indels
composition on Day 3 and Day 11 of in RRM2BOE HepG2 cells.
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Figure 4-6. A drug-induced RRM2 to RRM2B subunit switch in HB cells.
(A.) Dose response curves of HepG2 and HB214 cells to the indicated chemotherapeutic
agents and RRM2 inhibitors. (B.) RRM2 and RRM2B immunoblotting of HepG2 and
HB214 cell lysates after treatment with the indicated drugs. (C.) RNR subunits mRNA
levels detected by RNAseq in HepG2 cells treated with cisplatin. (D.) RRM1 co-IP assay
using MK1775- and gemcitabine-treated HepG2 cells. (E.) A time-course study of RRM2
and RRM2B protein levels in cisplatin treated HepG2 cells by immunoblotting. p values
were calculated by Student t test: * < 0.05; ** <0.01; *** <0.001; ****<0.0001.
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binding to RRM1 to form the RNR complex. With the help of Dr. Nikolai Timchenko,
we were able to immunoprecipitate RRM1 using MK1775- and gemcitabine-treated
HepG2 cells which showed an evident RRM2B-RRM1 binding dominant over RRM2RRM1 binding (Figure 4-6D). The elevated RRM2 in the Co-IP samples is possibly
due to larger treatment batches needed for Co-IP versus western blotting. A more
detailed time course study on cisplatin treated HepG2 cells revealed an induction of
RRM2 within the first 24 hours before its level started decreasing, while increase in
RRM2B levels occurred around 18-24 hours (Figure 4-6E). The other RNR subunit,
RRM1, had consistent expression following treatment to chemotherapy except for the
highest concentrations tested (Figure 4-6C, and Figure 4-7).
RRM2B has been shown to be regulated by the tumor suppressor TP53 and has
even been shown to bind to RRM2B in HepG2 cells in untreated conditions.232, 233 HepG2
cells have a wildtype TP53 gene.234 When examining HepG2 cells treated with cisplatin,
triapine and gemcitabine, we found that there was a well correlated increase in TP53 and
RRM2B protein levels with increasing drug concentrations (Figure 4-8A). We found in
two HCC cell lines with TP53 mutations, PLC/PRF/5 and Hep3B,235 treatment with
gemcitabine and a common HCC drug sorafenib failed to induce RRM2B as they did in
HB cells (Figure 4-8B)
To determine if this RRM2 to RRM2B subunit switching induced by drug
treatment also occurred in vivo, we treated HB214 subcutaneous models with saline or
irinotecan for two weeks and examined RRM2 and RRM2B levels via RNAscope.
Compared to the untreated HB214 tumors, the treated tumors showed a marked loss of
the typical punctate signals of RRM2 mRNA in many areas as well as the loss of the
tight association between RRM2 and cell proliferation indicated by Ki67 IHC (Figure
4-9a-f). RRM2 RNAscope staining on the treated HB214 tumors also showed an
unusually high staining background that was never observed in untreated tumors,
suggesting a potential RRM2 mRNA degradation under drug treatment (Figure 4-9
d vs. e and f). On the other hand, irinotecan-treated HB214 tumors showed an evident
increase in RRM2B mRNA signals compared to the control tumors, particularly in
stressed areas with reduced RRM2 mRNA signals (Figure 4-9 g-i). These in vitro and
in vivo results, together, demonstrate an intriguing drug-induced RNR M2 subunit
switching from RRM2 to RRM2B in HB cells.

Both RRM2 and RRM2B Contribute to HB Cell Drug Resistance, but Only RRM2B
Supports Post-treatment Recovery
To determine the involvement of RRM2 and RRM2B in HB cell drug response,
we treated TdT, RRM2OE and RRM2BOE HepG2 cells with six common liver cancer drugs
and the two RRM2 inhibitors triapine and MK1775. We found overexpression of RRM2
resulted in a slight increase in the IC50 of all the drugs tested except for SN38 (Figure
4-10A, B). RRM2BOE HepG2 cells also showed a limited increase in drug resistance in an
extent less than RRM2OE cells. Compared to control TdT cells, RRM2BOE cells showed no
differences in response to the two RRM2 inhibitors in addition to SN38
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Figure 4-7. RRM1 is more stable than RRM2 and RRM2B following treatment.
(A.) RRM1 immunoblotting in HepG2 and HB214 cells treated with cisplatin and
MK1775, GAPDH used as loading control.
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Figure 4-8. Drug-induced RRM2B upregulation in HB cells is associated with
TP53.
(A.) TP53, RRM2 and RRM2B immunoblotting in HepG2 cells treated with cisplatin,
triapine, and gemcitabine. (B.) RRM2 and RRM2B immunoblotting in two HCC cell
lines PLC/PRF/5 and Hep3B, and HepG2 cells treated with sorafenib and gemcitabine.
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Figure 4-9. Drug-induced RRM2 to RRM2B subunit switch occurs in vivo.
Ki67 IHC (a-c), RNAscope for RRM2 (d-f) and RRM2B (g-i) in untreated and irinotecan
treated HB214 tumors. Images on the same row share the same scale bar.
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Figure 4-10. Both RRM2 and RRM2B contribute to HB cell drug resistance, but
only RRM2B supports the post-treatment recovery of HB cells.
(A.) Dose response curves of TdT, RRM2OE and RRM2BOE HepG2 cells to the indicated
drugs. (B.) List of the drug IC50 values and their comparisons between TdT, RRM2OE
and RRM2BOE HepG2 cells. (C.) 12-day colony formation assay of the TdT, RRM2OE and
RRM2BOE HepG2 cells following cisplatin treatment at the indicated concentrations. (D.)
Quantitative comparison the of area occupied by cells in (C). p values were calculated by
Extra Sum of Square F test or Student t test: * < 0.05; ** <0.01; *** <0.001;
****<0.0001.
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(Figure 4-10A, B), consistent with the specificity of these two inhibitors to RRM2.
Since we have shown that elevation of RRM2B is maintained following treatment
for 72 hours, we suspected that RRM2B might function mostly to improve the fitness of
HB cells that had survived chemotherapy. To test this hypothesis, we treated TdT,
RRM2OE and RRM2BOE HepG2 cells with cisplatin, the most commonly used drug for
HB, for the same 72-hour time point at different concentrations. We then washed and
removed the dead cells and seeded the remaining live cells at a low density and allowed
them to recover for 12 days with fresh media. We found that, while no difference in the
number of colonies grown from the untreated cells, RRM2BOE cells exhibited a
significantly higher ability to “relapse” from cisplatin treatment compared to the TdT and
RRM2OE cells (Figure 4-10C, D). TdT and RRM2OE cells were similar in their ability to
grow back after cisplatin treatment (Figure 4-10C, D).
To further confirm that RRM2B is important to the recovery of HB cells
following treatment, we used the RRM2B knockout (RRM2BKO) cells from (Figure
4-4E). We first wanted to verify that failing treatment, there was still no induction of
RRM2B in these cells following cisplatin treatment (Figure 4-11A). We then tested the
two KO cell lines against standard liver cancer chemotherapy agents as well as the two
RRM2 inhibitors to check for changes in drug resistance. Interestingly, both RRM2BKO
cell lines showed no significant change in IC50 values to any of the drugs we tested
(Figure 4-11B) showing that RRM2B is less important for initial drug response.
However, when it came to post-treatment recovery both RRM2BKO cell lines showed a
significant decrease in their ability to form colonies at all concentrations tested following
treatment with cisplatin when compared to the wild type HepG2 cells (Figure 4-11C, D).
We then wanted to validate these results in the HB PDX cell lines HB214. Using the
same CRISPR/Cas9 system, we were able to successfully KO RRM2B in HB214
(HB214KO) (Figure 4-12A). HB214KO cells showed a slight increase in IC50 values when
compared to the parental cell line to some of the drugs tested including vincristine,
doxorubicin, SN38, and MK1775 (Figure 4-12B). When HB214KO cells were tested for
post-treatment recovery, we saw a complete loss of colony formation ability when
RRM2B was KO in HB214 compared to the control (Figure 4-12C, D). We then wanted
to see if the RRM2B KO phenotype could be rescued by expression of exogenous
RRM2B. Rescue cells (RRM2BKO/Res) were generated by transfection of the HepG2
RRM2BKO cells with the RRM2B overexpression vector (Figure 4-13A). We then
compared these RRM2BKO/Res cells to their KO controls in their growth, drug response,
and post-treatment recovery. Rescue of RRM2B did not have any change on cell growth
similar to the other RRM2B manipulated cells (Figure 4-13B and Figure 4-4B). Both
rescue cells lines showed an increase in IC50 values to several of the drugs tested
comparable to the RRM2BOE cell line (Figure 4-13C and Figure 4-14). Finally, RRM2B
re-expression was able to partially rescue the colony formation ability of the KO cells at
lower concentrations of cisplatin but not at the high concentration (Figure 4-13D, E).
These results suggest RRM2 plays a more important role in cell growth and initial drug
response, however, RRM2B plays a critical role in supporting the post-treatment
recovery of HB cells.
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Figure 4-11. Knockout of RRM2B had no effect on drug resistance while
decreasing post-treatment recovery in HepG2 cells.
(A.) RRM2 and RRM2B immunoblotting in untreated and cisplatin treated RRM2BKO
HepG2 cells. (B.) Dose response curves of HepG2 (Ctrl), RRM2BKO1, and RRM2BKO1
HepG2 cells to the indicated drugs. (C.) 12-day colony formation assay of the HepG2
(Ctrl), RRM2BKO1, and RRM2BKO1 HepG2 cells following cisplatin treatment at the
indicated concentrations. (D.) Quantitative analysis of area occupied by cells in (C). p
values were calculated by Extra Sum of Square F test or Student t test: * < 0.05; **
<0.01; *** <0.001; ****<0.0001.
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Figure 4-12. Knockout of RRM2B had minimal effect on drug resistance while
decreasing post-treatment recovery in HB PDX cell line HB214.
(A.) RRM2 and RRM2B immunoblotting in untreated and cisplatin treated RRM2BKO
HB214 cells. (B.) Dose response curves of HB214 and RRM2BKO1 HB214 cells to the
indicated drugs. (C.) 12-day colony formation assay of the HB214 and RRM2BKO1
HB214 cells following cisplatin treatment at the indicated concentrations. (D.)
Quantitative analysis of area occupied by cells in (C). p values were calculated by Extra
Sum of Square F test or Student t test: * < 0.05; ** <0.01; *** <0.001; ****<0.0001.
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Figure 4-13. Re-expression of RRM2B can rescue partial cell recovery in HB cells.
(A.) RRM2 and RRM2B immunoblotting in RRM2BKO and RRM2BKO/Res HepG2 cells.
(B.) Growth curves of HepG2 (Ctrl), RRM2BKO1, RRM2BKO1, RRM2BKO1/Res, and
RRM2BKO2/Res HepG2 cells. (C.) Dose response curves of RRM2BKO1 and RRM2BKO1/Res
HepG2 cells to the indicated drugs. (D.) 12-day colony formation assay of the HepG2
(Ctrl), RRM2BKO1, RRM2BKO1, RRM2BKO1/Res, and RRM2BKO2/Res HepG2 cells following
cisplatin treatment at the indicated concentrations. (E.) Quantitative analysis of area
occupied by cells in (D). p values were calculated by Extra Sum of Square F test or
Student t test: * < 0.05; ** <0.01; *** <0.001; ****<0.0001.
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Figure 4-14. Drug response curves of control, RRM2BKO2, and RRM2BKO2/Res
HepG2 cells.
Dose response curves of RRM2BKO2 and RRM2BKO2/Res HepG2 cells to the indicated
drugs. ). p values were calculated by Extra Sum of Square F test: * < 0.05; ** <0.01; ***
<0.001; ****<0.0001.
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RRM2 and RRM2B Are Involved in Distinct Cellular Processes in HB Cells and
Patient Tumors
With the help of Dr. Qingfei Pan we performed a series of transcriptomic analyses
of the HB cell and patient tumors in an effort to understand the systemic involvement of
RRM2 and RRM2B in HB tumorigenesis. Using these patient transcriptomic profiles,
which were divided into RRM2High and RRM2BHigh samples, we were able to identify a
set of RRM2 and RRM2B hub genes whose expression was highly correlated with RRM2
and RRM2B expression respectively, including both the upstream regulators and
downstream targets (Figure 4-15A, B). RNA-seq data of 374 HCC patient tumors in The
Cancer Genome Atlas (TCGA) database were also downloaded and analyzed
simultaneously since we have shown that RRM2 was also tightly associated with HCC
progression. We found that the hub genes were similar for each gene between HB and
HCC patient tumors (Figure 4-15A, B), while there was no overlap between RRM2 and
RRM2B hub genes in either tumor types (Figure 4-16A). A hypergeometric distribution
method found that RRM2 hub genes are mostly enriched in the pathways involved in cell
proliferation and DNA repair (RRM2-associated pathways, or PTWAYRRM2) while
RRM2B hub genes participated strongly in stress and inflammatory response pathways
(RRM2B-associated pathways, or PTWAYRRM2B) (Figure 4-16B). These enriched
pathways correlate with the observed phenotypes we have seen in our RRM2 and RRM2B
manipulated cells and suggest that RRM2 and RRM2B could be playing similar roles in
HB patient tumors.

A Reversed RRM2B to RRM2 Subunit Switching in HB Cells Recovering from
Drug Treatment
Our data suggested that inhibiting RRM2B would work as an effective
combinatorial treatment to standard chemotherapies. However, no RRM2B-specific
inhibitors have been developed, likely due to the low expression of this RNR M2 subunit
in growing tumor cells. We tested two drugs that could potentially inhibit RRM2B,
deferoxamine236 and KU60019237, however, neither of which showed RRM2B-specific
inhibition at the protein level, nor in our RRM2BOE cells (Figure 4-17A, B). Since our
data indicated that RRM2 was important to HB cell growth, we hypothesized that HB
cells would regain RRM2 expression in order for them to resume growth after treatment.
In turn, RRM2 inhibition might be an effective approach to prevent HB relapse. When
cisplatin treated HepG2 cells were allowed to regrow, we found that the level of RRM2
did come back up and became the dominant M2 subunit again while RRM2B levels
decreased (Figure 4-18A). This reversed RRM2B to RRM2 switching occurred quickly
and at a high level in cells that were initially treated with a relatively low concentration of
cisplatin (3.1 mM), and much more slowly and at a markedly lower level in cells treated
with a high dose of cisplatin (12.5 mM) (Figure 4-18A). We then moved onto the in vivo
tumors and found an expected reduction in RRM2B mRNA level over time in HB214
tumors post irinotecan treatment, and the reestablishment of strong RRM2 expression in
proliferating cells (Figure 4-18B, a-f). In an HB PDX derived from a recurrent patient
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Figure 4-15. Identification of hub genes associated with RRM2 and RRM2B in HB
and HCC patient tumors.
(A.) Microarray data from 46 HB patient tumors and sequencing data from 374 HCC
patients tumors were divided into thirds to separate RRM2High samples and RRM2BHigh
samples. (B.) Hub genes associated with RRM2 and RRM2B in HB and HCC patient
cohorts inferred by SJARACNe. Edge width is corresponding to the correlation strength
measured by mutual information. Red and blue edges indicate positive and negative
correlations of each hub gene, respectively.
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Figure 4-16. RRM2 and RRM2B are involved in distinct cellular processes in HB
and HCC patient tumors.
(A.) Venn plot showing the overlap statistics of the four hub gene list. (B.) Gene set
enrichment analysis of HALLMARK and KEGG gene sets of the 4 hub gene lists using
Fisher’s Exact Test. The size and color intensity indicate the odds ratio and statistical
significance, respectively. The p values of the bar plot were combined from HB and HCC
primary patient cohorts using the Stouffer method.
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Figure 4-17. No effective RRM2B inhibitors.
(A.) Immunoblot for RRM2 and RRM2B in HepG2 cells treated with deferoxamine and
KU60019. (B.) Dose response curves of TdT, RRM2OE, and RRM2BOE HepG2 cells to
deferoxamine and KU60019. p values were calculated by Extra Sum of Square F test: * <
0.05; ** <0.01; *** <0.001; ****<0.0001.
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Figure 4-18. A reversed RRM2B to RRM2 subunit switching in relapsed HB cells
and tumors.
(A.) RRM2 and RRM2B immunoblotting of HepG2 cells recovered from the indicated
cisplatin treatment. (B.) Ki67 IHC and RRM2 and RRM2B RNAscope HB214 tumors
post irinotecan treatment and a HB PDX model derived from a recurrent patient tumor.
All images on the same row share the same scale bar. (C.) ZIP synergy analysis of the
two RRM2 inhibitors in combination with SN38 in HB214 cells. (D.) Tumor volume
measurements in mice treated with the indicated drug or drug combination. Arrow: drug
withdraw on Day 21. (E.) Tumor volume measurements in mice treated with the
indicated drug or drug combination. Arrow: drug withdraw on Day 14. MK1775 was
maintained in the last group (red line). (F.) RRM2 and RRM2B immunoblotting of the
HB214 tumors collected post the indicated treatment. ZIP scores calculated using
SynergyFinder2.0.196
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tumor (HB243)230, we similarly found high levels of RRM2 and low levels of RRM2B in
Ki67+ cells (Figure 4-18B, d-l,).
Based on these results, we tested the efficacy of combining RRM2 inhibitors with
chemotherapy in preventing HB relapse. To identify the synergistic combinations, we
first tested HepG2 and HB214 cells for combinatorial treatments of the two RRM2
inhibitors, triapine and MK1775, with other chemotherapeutic agents in vitro. We found
that SN38, the active form of irinotecan, showed good synergy with both triapine and
MK1775 in HB214 (Figure 4-18C). With the help of Dr. Stefano Cairo and Dr. Emilie
Endersie we then tested triapine/irinotecan and MK1775/irinotecan combinatorial
treatment in the HB214 subcutaneous PDX model. Triapine treatment caused rapid body
weight loss and all animals had to be removed from the study early (data not shown).
Treatment with irinotecan and a low dose of MK1775, which had minimal toxicity or
anti-tumor efficacy by itself, showed no additional benefit in tumor suppression
compared to irinotecan alone during the three weeks of treatment. However, a modest but
statistically significant delay in tumor relapse was observed in mice which previously
received the MK1775/irinotecan combinatorial treatment (Figure 4-18D). Based on this
result, we tested the possibility of continuing this low dose MK1775 as a “maintenance
therapy” in a second in vivo test. We shortened MK1775/irinotecan combinatorial
treatment to two weeks and then MK1775 alone afterwards. We found that, compared to
irinotecan monotherapy, this MK1775/irinotecan-MK1775 treatment regimen was able to
delay tumor relapse for approximately 10 days (Figure 4-18E). We collected tumor
samples from different post-treatment time points and confirmed there was an evident
subunit switching from RRM2 to RRM2B in tumors right after treatment and a reversed
switching in relapsed tumors (Figure 4-18F). These results show a promise in combining
RRM2 inhibition with chemotherapy to prevent HB relapse. Future optimization on the
drug dose will be necessary as this low-dose of MK1775 we used was only able to delay
but not prevent the eventual tumor relapse in both tests.
Overall, out study demonstrates a subunit switching between RRM2 and RRM2B in HB
cells in the context of cell proliferation and survival (Figure 4-19). RRM2 switches to
RRM2B when drug treatment inhibits cell proliferation and induces stress; once helping
cells survive the stress, RRM2B switches back to RRM2 to support cell regrowth.
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Figure 4-19. A working model of RRM2 and RRM2B subunit switching in HB
growth, drug response, and relapse.
Schematic representation of the dynamic relationship between RRM2 and RRM2B.
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CHAPTER 5.

DISCUSSION

Rare pediatric cancers present one of the greatest challenges to the oncology
community because of the limited number of patients available for therapeutic and
biological investigations. HB is a very rare cancer but the most common liver cancer in
children. HB is also one of the most genetically simple cancer types with low numbers of
genomic abnormalities.126 Little is known how some HB tumors, with minimal alterations
in their genomic profiles, manage to progress into highly advanced stages and develop
drug resistance. Studies have shown that the drug resistance of many adult solid tumors
can be mediated by an adaptive and often reversible cellular state tumor cells turn on
under stressful conditions.211, 212, 238, 239 Past HB studies have mainly focused on the
“natural” biology driving advanced tumor progression in an effort to find better treatment
for the high-risk forms of this disease that are resistant to standard treatment.43, 195, 240
With the increasing appreciation of cancer cell plasticity in drug resistance through
studies in adults, understanding mechanisms that enable HB cells to survive drug
treatment and support subsequent relapse has become a potential path leading to a better
treatment of this pediatric cancer.
RRM2 is well known for its upregulation in adult solid tumors and its essential
role in supporting cell proliferation.217-221 RRM2B has also been reported to contribute
to stress response and drug resistance of cancer cells.111, 115, 241 RRM2B subunit
switching had been reported before under hypoxic conditions.116 However, we believe
this work is one of first studies that has revealed a dynamic, reversible switching
between the two RNR M2 subunits under chemotherapy and depicted a biological
picture on how HB cells transit between a growing state and a surviving state from a
point of RNR dynamics.
In Figure 4-7 I show this dynamic switching of the two RNR2 subunits
following different chemotherapy treatments. However, this is from a pool of cells, and
it is possible that this response is not occurring in every cell and that some cells have
high RRM2B while others do not. Validating this subunit switching at the single cell
level would further prove the importance of RRM2B in response to chemotherapy. This
could be done by attaching a fluorescent tag to endogenous RRM2 (GFP) and RRM2B
(RFP). Upon treatment you would be able to perform live cell imaging of a single cell
and monitor the change in fluorescence from green to red and actively monitor the
dynamic relationship between these two proteins.
The mechanism of RRM2B induction following chemotherapy needs to be
investigated further. We show in Figure 4-9 that there is an association between TP53
expression and RRM2B expression in HepG2 cells. There is also chromatin
immunoprecipitation sequencing (ChIP-seq) data available that shows binding of TP53
to RRM2B in HepG2 cells233. However, this ChIP-seq was performed in untreated
HepG2 cells. This same experiment should be done in treated HepG2 cells with
increasing concentrations of therapeutic agents to further validate TP53 dependent
induction of RRM2B following treatment. Furthermore, obe could introduce loss of
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function mutations of TP53 in to HepG2 cells such as R249S242 and test whether is
similarly induces RRM2B expression both at the RNA level and protein level following
treatment. One could then re-introduce wild type TP53 to see if induction can be
rescued.
As mentioned previously, RRM2 is cell cycle regulated, and therefore has been
a target for chemotherapy as a way of targeting proliferative cells, several of which I
mentioned earlier (Chapter 2). There are two current downsides to RRM2 inhibitors.
First is the lack of specificity of these inhibitors. Several compounds that inhibit
RRM2, specifically target the non-heme iron group in RRM2. These compounds will
also target other metalloproteins which can lead to severe side effects or decrease the
effectiveness of these compounds due to the saturation of multiple targets. The second
downside is that a number of drugs need the RRM1/RRM2 holocomplex in order for
them to engage the binding pocket. This leads other compounds to compete for the
binding pocket such as nucleosides and allosteric regulators and thereby decrease the
drug’s efficacy. Both reasons highlight the need for RRM2 specific inhibitors.
siRNAs have been developed to target RRM2 and have shown effectiveness when
working in combination with other drugs in several cancer types including pancreatic
adenocarcinoma,87 clear cell renal carcinoma,80 and CML.83 However, difficulties in
siRNA delivery makes siRNA-based therapy clinically challenging. In fact, a few
different applications have been developed using liposomes or nanoparticles which
increase the efficacy of the siRNA by increasing the solubility and half-life.220 Although
these delivery systems have seen increased efficacy in vivo in pancreatic carcinoma221
and even HCC 222, more clinical validation is warranted.
Our study suggests that RRM2B-specific inhibitors, when developed, can be very
promising anti-cancer agents when combined with standard treatment for its non-essential
role in normal cells but its critical role in drug resistance and cancer relapse. The idea of
targeting the cellular response to stress is not novel. Programed death receptor and ligand
1 (PD-1/PD-L1) plays an important role in the ability of cytotoxic T cells to kill cancer
cells with an increased expression of PD-L1 inducing T cell anergy thus allowing cancer
cells to evade killing. It has been reported that stress response from chemotherapy causes
an increase in translation of PD-L1 thus decreasing the efficacy of cytotoxic T cells.243
Targeting of PD-L1 with a PERK inhibitor that increased the activity of cytotoxic T cells
showed synergistic effects in vivo.
In that regard, I believe determining the therapeutic value of RRM2B warrants
further investigation. In Chapter 4 I was able to successfully knockout RRM2B in two
HB cell lines. While we did see a decrease in colony formation in the KO cells, a
common issue with single cell selection following a gene KO, are cells losing
dependency of the selected target. However, using a degradation tag (dTAG) system
would be able to work around this problem. dTAGs are a method of targeted degradation
that by attaching a chemical probe to the target of interest, once can initiate its selective
degradation with a heterobifunctional degrader that will bridge the probe (and target of
interest) to an E3 ubiquitin ligase.244 With this system, RRM2B could be specifically
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degraded without influencing the dependencies in cells and in mice and would be able to
more accurately determine the therapeutic value of RRM2B.
There have not been any reported specific inhibitors of RRM2B until the
discovery of compound DFO, mentioned in Chapter 2, which was able to bind to
RRM2B with higher affinity than to RRM2. When this compound was tested in our
hands, we saw no clear inhibition of RRM2B or RRM2 Figure 4-18. The lack of
RRM2B inhibitors could be because of two main reasons. First is the lack of RRM2B
expression in many tumors. Even though there have been some tumors reported to have
elevated expression mentioned before, most tumors have low levels unless the tumor is
actively stressed recently via hypoxia or chemotherapy. Second is the homology
between RRM2 and RRM2B subunits. It would be difficult to design small molecule
inhibitors to specifically bind to RRM2B without binding to RRM2 as well.
siRNA have been used to target RRM2B in a similar fashion as RRM2. siRNA
inhibition of RRM2B was able to increase sensitivity to radiation in esophageal
squamous cell carcinoma245 and increase the efficacy of 5-FU in oral cancer.246 These
findings are similar to our own suggesting that inhibition of RRM2B could prevent
cells from responding to stress from chemotherapy treatment.
One potential method that we would like to try in the future is targeting RRM2B
with the use of Proteolysis Targeting Chimeras (PROTACs). PROTACs are a unique
targeting technology that makes use of the host’s own machinery to degrade the target.
PROTACs can bind to their protein of interest (POI) and bring it to the proximity of an
E3 ubiquitin ligase, resulting in a stable PROTAC-POI-E3 ternary complex and
subsequently proteasomal degradation.247, 248 One of the advantages of using PROTACs
is that the inhibition process is not impeded by traditional targeting stumbling blocks
such as competition of substrates or occupancy driven events. This allows PROTACs to
achieve greater efficacy at lower concentrations.249
Finally, even though RRM2 and RRM2B perform similar enzymatic functions
when bound to RRM1, it is clear from the hub gene analysis (Figure 4-16) that these
two proteins serve different functions in pediatric liver cancer. Elucidating this dynamic
relationship needs further studies. One possible relationship between RRM2B and cell
survival is with the mitochondria and reactive oxygen species (ROS). As mentioned in
Chapter 2 RRM2B is also responsible for the synthesis of mtDNA. In HB, cisplatin is
the most commonly used drug for treatment. Cisplatin not only damages nuclear DNA,
it targets mtDNA as well.250 Excessive mtDNA damage can lead to increase in
oxidative stress and the increased production of ROS and eventual cell death.251
RRM2B has been shown to suppress the oxidative stress pathway23, contain catalase
activity to scavenge ROS252, and repair mtDNA under stress.253 The decrease in colony
formation observed in Chapter 4 could be due to the cells inability to handle the
oxidative stress and increase in ROS caused by cisplatin treatment leading to eventual
cell senescence and death. This hypothesis could be tested by monitoring mitochondrial
activity before and after treatment in control cells as well as the RRM2B KO and OE
cells we generated. A common gene for monitoring mitochondrial activity is
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mitochondrial transcription factor A (TFAM).254 One could also monitor active ROS
production in live cells using fluorescent imaging or flow cytometry. This would be
able to determine whether inhibition of RRM2B increases ROS in the cells.
Taken together, in this study, we showed that upregulation of RRM2 is strongly
associated with high-risk HB. In an attempt to suppress this molecule with standard
chemotherapy as well as its inhibitors, we found that, when RRM2 was effectively
suppressed by these drugs, there was a surprising induction of RRM2B, another RNR
M2 subunit that shares a high protein homology with RRM2. We confirmed that
RRM2B had a lower RNR enzymatic activity than RRM2 as reported and had limited
participation in the proliferation or the initial drug response of HB cells. However, we
found that RRM2B was critical to the fitness of the HB cells that survived initial drug
treatment, allowing them to relapse much more efficiently post drug treatment. When
HB cells resumed proliferation during relapse, RRM2 became the dominant RNR M2
subunit again and RRM2B gradually dropped to its low, pre-treatment level. Adding a
low-dose of RRM2 inhibitor MK1775 to irinotecan was able to delay the tumor relapse
in an HB PDX model compared to irinotecan treatment alone. Computational analysis
of publicly available HB and HCC patient transcriptomic profiles and our RNRmanipulated HB cells revealed distinct cellular network associated with these two RNR
M2 subunits. Consistent with the cell and tumor phenotypes we observed, PTWAYRRM2
is primarily inolved in cell proliferation and DNA repair while PTWAYRRM2B
participates heavily in stress and inflammatory responses.
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